Introduction {#s1}
============

Parkinson\'s disease (PD) is the second most common neurodegenerative disorder and there is no cure for this progressive illness ([@bib27]). Mutations in PINK1, a mitochondria-localized serine--threonine kinase, and Parkin, an E3 ubiquitin ligase, lead to autosomal recessive forms of the disease ([@bib31]; [@bib60]). Genetic studies in *Drosophila* first demonstrated that *PINK1* and *parkin* act in the same genetic pathway, with *PINK1* positively regulating *parkin*, to regulate mitochondrial integrity and function ([@bib12]; [@bib49]; [@bib64]). Mitochondrial morphology is maintained by a balance between two opposing actions, mitochondrial fusion that is promoted by *mitofusin (mfn)* and mitochondrial fission that is controlled by *Dynamin-related protein 1 (Drp1)* ([@bib7]; [@bib46]). Genetic studies in *Drosophila* have shown that downregulation of *mfn* or overexpression of *drp1* suppresses multiple phenotypes associated with lack of *PINK1* or *parkin,* including defects in mitochondrial integrity, cell death, tissue health, and flight ability ([@bib15]; [@bib53]; [@bib65]). Parkin ubiquitinates Mfn and promotes Mfn degradation ([@bib54]; [@bib70]). However, it is not clear if increased *mfn* or decreased *drp1* levels are sufficient to cause the phenotypes observed in *PINK1* or *parkin* mutants.

In addition to mitochondrial dynamics, the *PINK1/Parkin* pathway promotes mitophagy, selective autophagic degradation of defective mitochondria in mammalian cells. Accumulation of mitochondrial damage can result in loss of mitochondrial membrane potential. This leads to recruitment of Parkin to the depolarized mitochondria, ultimately resulting in autophagic degradation of these mitochondria ([@bib42]; [@bib16]; [@bib22]; [@bib23]; [@bib41]; [@bib43]; [@bib47]; [@bib59]; [@bib63]; [@bib8]). Parkin-mediated mitophagy also occurs in mouse cortical neurons and heart muscle ([@bib6]; [@bib11]). An important step during this process is Parkin-dependent ubiquitination of Mfn and other substrates, followed by their proteasome-dependent degradation ([@bib59]; [@bib8]). Relevant to PD, *PINK1* and *parkin* mutant fibroblasts from PD patients also show deregulation of mitochondrial dynamics and modest defects in the clearance of mitochondria ([@bib55], [@bib56]).

An important puzzle in the field of PD research is why mice lacking *PINK1* or *parkin* bear only subtle phenotypes related to dopaminergic neuronal degeneration or mitochondrial morphology change ([@bib48]; [@bib52]; [@bib51]; [@bib32]; [@bib18]; [@bib21]; [@bib24]; [@bib33]; [@bib1]). This raises the possibility that other mechanisms may compensate for loss of *PINK1* or *parkin*. Indeed, when *parkin* is knocked down in adult dopaminergic neurons rather than during development, more striking neuronal degeneration is observed ([@bib14]; [@bib57]; [@bib36]). However, the molecular mechanisms by which loss of *PINK1/parkin* function can be compensated are not known.

Mitochondrial ubiquitin ligase 1 (MUL1), also known as mitochondrial-anchored protein ligase (MAPL) ([@bib45]), mitochondrial ubiquitin ligase activator of NF-kB (MULAN) ([@bib38]), or growth inhibition and death E3 ligase (GIDE) ([@bib67]), was identified as an E3 protein ligase by three independent groups. Work in mammalian systems shows that MUL1 has small ubiquitin-like modifier (SUMO) ligase activity, stabilizing Drp1 ([@bib28]; [@bib5]), or ubiquitin ligase activity, degrading Mfn ([@bib39]). As expected from a protein with these proposed biochemical activities, *MUL1* expression in mammalian cells results in smaller and more fragmented mitochondria ([@bib38]; [@bib45]). However, the consequences of loss of *MUL1* in vivo have not been reported in any organism.

In this study, we show that overexpression of *mfn* is sufficient to recapitulate many *PINK1/parkin* mutant phenotypes, underlining the central importance deregulation of this protein has for PD pathogenesis. Expression of wild-type MUL1, but not a ligase-dead version, suppresses *PINK1* or *parkin* mutant phenotypes, and those due to *mfn* overexpression in *Drosophila*. Conversely, removing *MUL1* in *PINK1* or *parkin* null mutants results in enhanced phenotypes as compared with the single mutants, suggesting that *MUL1* acts in parallel to the *PINK1/parkin* pathway. MUL1 physically binds to Mfn and promotes its ubiquitin-dependent degradation. MUL1, but not a ligase-dead version, also regulates Mfn levels and mitochondrial morphology in human cells. Experiments in *Drosophila* and mammalian systems suggest that *MUL1* regulates *mfn* through a pathway parallel to that of *PINK1/parkin* pathway. Finally, knockdown of *MUL1* from *parkin* knockout mouse cortical neurons augments mitochondrial damage and induces neurodegeneration-like phenotypes than does removing either gene alone. Together, these results suggest that *MUL1* plays an important compensatory function in organisms or cells lacking *PINK1/parkin*.

Results {#s2}
=======

Overexpression of *MUL1*, but not a ligase-dead form, suppresses *PINK1* and *parkin* mutant phenotypes in dopaminergic neurons and muscle {#s2-1}
------------------------------------------------------------------------------------------------------------------------------------------

We identified *MUL1* as a novel suppressor of *PINK1/parkin* mutant phenotypes. Human MUL1 contains two transmembrane (TM) domains and a highly conserved C-terminal ring finger (RNF) domain. Topological studies suggest that the two TM domains anchor the protein to the mitochondrial outer membrane, with the RNF domain facing the cytosol ([@bib38]). *Drosophila MUL1* (CG1134) encodes a protein with a similar domain structure, and 52% amino acid similarity to human MUL1 ([Figure 1A,B](#fig1){ref-type="fig"}).10.7554/eLife.01958.003Figure 1.Overexpression of *MUL1*, but not *MUL1 LD*, suppresses *PINK1*/*parkin* mutant phenotypes.(**A**) Protein domain organization of Drosophila MUL1. TM1, TM2, and RNF represent transmembrane domains 1 and 2, and the RING Finger domain, respectively. The position of the mutation in the ligase dead (LD) version of MUL1 is marked with a red asterisk. (**B**) Sequence alignment of MUL1 in various species in the highly conserved RNF domain. A highly conserved histidine residue (marked as red) was mutated to alanine in MUL1 LD, ablating ligase activity. (**C**--**C″**) Dopaminergic neurons stained with an anti-TH antibody in red and mitochondria labeled with mitoGFP in green. Neurons in the PPL1 cluster are shown. While mitochondria in wild-type dopaminergic neurons are dispersed (**C**), mitochondria in *PINK1* mutant dopaminergic neurons are clumped (**C′**, white arrow heads). This phenotype is suppressed by *MUL1* overexpression driven by TH-Gal4 (**C″**). Scale bars: 10 µm. (**D**--**E″**'' and **J**--**M″**'') Confocal images of the IFM from thoraces double labeled with mitoGFP and phalloidin (red) (**D**--**D″**, **J**--**J″**, **L**--**L″**), or double labeled with mitoGFP and TUNEL (red) with lower magnification (**E**--**E″**, **K**--**K″**, **M**--**M″**). Scale bars: 5 µm. *MUL1* overexpression is driven by Mef2-Gal4. In wild-type (**D**), mitochondria have a regular size and shape, and are localized in between myofibrils. In *PINK1* mutants (**D′**), mitochondrial size becomes irregular, and the GFP signal is reduced. Large mitochondrial clumps also appear. *PINK1* mutant muscle is TUNEL-positive (**E′**). (**F**--**F″**) Touidine blue staining of muscle. Compared with the wild-type (**F**), *PINK1* mutant muscle shows vacuolation indicating muscle degeneration (**F′**). These *PINK1* mutant phenotypes (**D′**, **E′**, **F′**) are almost completely suppressed by *MUL1* overexpression (**D″**, **E**″, **F″**). (**Ga**--**Ga**″, **Gb**--**Gb**″) EM images of mitochondria in muscle. (**Gb**--**Gb″**) Single mitochondrion (outlined with dashed lines) from white boxes in **Ga**--**Ga″**. Scale bars: 1 µm (**Ga**--**G″a**) 0.5 µm (**Gb**--**G″b**). In wild-type (**Ga** and **Gb**), mitochondria have compact and organized cristae whereas mitochondria from *PINK1* mutants (**Ga′**, **Gb′**) are swollen with fragmented cristae, and this is rescued by *MUL1* overexpression (**Ga″**, **Gb″**). (**H**) Images of thoraces. Arrows point to thoracic indentations due to muscle degeneration. Compared with WT, *PINK1* mutants have thoracic indentation due to muscle degeneration. *MUL1* overexpression, but not *MUL1 LD* overexpression, suppresses *PINK1* mutant thoracic indentation. (**I**) qPCR analysis shows that *MUL1* and *MUL1 LD* mRNA are expressed at similar levels in muscles. The data are shown as the mean ± SEM from three experiments (RNA from ten 5-day-old fly thoraces for each genotype). The statistical analysis was done using One-way ANOVA with Tukey\' multiple comparisons test. ns: not statistically significant. *MUL1 LD* overexpression in the *PINK1* mutant background does not suppress the formation of mitochondrial clumps (**J″**) or TUNEL-positivity (**K″**). (**L**--**M″**) Overexpression of *MUL1*, but not *MUL1 LD,* suppresses *parkin* mutant phenotypes.**DOI:** [http://dx.doi.org/10.7554/eLife.01958.003](10.7554/eLife.01958.003)10.7554/eLife.01958.004Figure 1---figure supplement 1.MUL1, but not its ligase-dead version (MUL1 LD), is able to self-ubiquitinate in vitro.In vitro ubiquitination assay using purified Drosophila MUL1 and MUL1 LD. Western blot probed with anti-GST antibody detects unmodified forms of both MUL1 and MUL1 LD (lower panel, arrowhead). In addition, MUL1 has high molecular weight bands suggesting self-ubiquitination of MUL1. When the blot was probed with antibodies against poly-ubiquitinylated protein, only MUL1 show a smear of high-molecular-weight ubiquitinated bands, but not MUL1 LD (upper panel). The result confirms that mutation in MUL1 LD completely abolishes its ligase activity.**DOI:** [http://dx.doi.org/10.7554/eLife.01958.004](10.7554/eLife.01958.004)

We overexpressed *MUL1* in various tissues using the UAS/GAL4 system ([@bib3]). *Drosophila* contains clusters of dopaminergic (DA) neurons in the adult brain. In wild-type DA neurons, mitochondria are dispersed in the cytosol ([Figure 1C](#fig1){ref-type="fig"}). In contrast, *PINK1* mutant DA neurons show abnormally clumped mitochondria ([Figure 1C′](#fig1){ref-type="fig"}, arrowheads) ([@bib49]), which can be suppressed by overexpression of *MUL1* ([Figure 1C″](#fig1){ref-type="fig"}).

We further characterized *MUL1*\'s effects on *PINK1/parkin* mutants in thoracic indirect flight muscle (IFM), which consists of well-organized muscle fibers, in which mitochondria fill spaces between myofibrils. *PINK1* null mutant flies have severe defects in mitochondrial morphology, including an overall reduction in mitochondria-targeted GFP (mitoGFP) signal and the presence of large mitoGFP clumps ([Figure 1D--D′,E--E′](#fig1){ref-type="fig"}). *PINK1* mutant muscle also shows extensive TUNEL-positive cell death ([Figure1E--E′](#fig1){ref-type="fig"}), muscle vacuolation, and degeneration ([Figure 1F--F′](#fig1){ref-type="fig"}). In addition, when examined under the electron microscopy (EM) level, many mitochondria are swollen with broken cristae ([Figure 1Ga--Ga′,Gb--Gb′](#fig1){ref-type="fig"}). At the level of the whole organism, *PINK1* mutants show a thoracic indentation due to IFM degeneration ([Figure 1H](#fig1){ref-type="fig"}). Strikingly, *MUL1* overexpression almost completely rescues all of the above *PINK1* mutant phenotypes ([Figure 1D″--F″,Ga″--Gb″,H](#fig1){ref-type="fig"}).

To determine if the E3 ligase activity of MUL1 is required for suppression of *PINK1* mutant phenotypes, we generated a ligase-dead form of *Drosophila* MUL1 (MUL1 LD) in which histidine 307, a highly conserved residue within the RNF domain, was mutated to alanine ([Figure 1A,B](#fig1){ref-type="fig"}). This mutation has been shown to abolish ligase activity of mammalian MUL1 ([@bib67]); in vitro ubiquitination assays confirm that *Drosophila* MUL1 LD lacks ligase activity ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). The expression levels of *MUL1* and *MUL1* LD in muscles are comparable ([Figure 1I](#fig1){ref-type="fig"}), and no mitochondrial clumps or muscle cell death are observed when *MUL1* or *MUL1* LD is overexpressed in wild-type animals ([Figure 1J,J′,K,K′](#fig1){ref-type="fig"}). Expression of *MUL1* LD does not suppress *PINK1* mutant phenotypes ([Figure 1H,J″,K″](#fig1){ref-type="fig"}). Overexpression of *MUL1* ([Figure 1L′,M′](#fig1){ref-type="fig"}), but not *MUL1* LD ([Figure 1L″,M″](#fig1){ref-type="fig"}), also suppressed *parkin* null mutant phenotypes. Thus, *MUL1* is a robust suppressor of *PINK1/parkin* mutants and this requires MUL1\'s ligase activity.

*MUL1* regulates mitochondrial morphology in *Drosophila* {#s2-2}
---------------------------------------------------------

As an E3 ligase anchored onto the mitochondrial outer membrane, MUL1 has been shown to have multiple substrates including Drp1 and Mfn ([@bib5]; [@bib39]). However, the consequences of loss of *MUL1* have not been reported in any organism. The P element, *MUL1*^*EY12156*^ (*MUL1*^*EY*^), inserted at 20 bp upstream of the *MUL1* start codon ([Figure 2A](#fig2){ref-type="fig"}), is a partial loss-of-function allele with reduced mRNA expression ([Figure 2B--C](#fig2){ref-type="fig"}). We performed imprecise excision of this P element and generated a large deletion allele, *MUL1*^*A6*^. *MUL1*^*A6*^, hereafter called the *MUL1* mutant, produces no detectable transcript ([Figure 2B--C](#fig2){ref-type="fig"}), and therefore is a null allele. Flies homozygous for *MUL1*^*A6*^ are viable. We also generated two independent RNAi constructs that target two different locations in the *MUL1* coding region. Flies expressing these constructs (*MUL1* RNAi lines) show the same phenotypes (see below) and reverse the suppression of *PINK1* mutant phenotypes observed upon *MUL1* overexpression ([Figure 2D](#fig2){ref-type="fig"}).10.7554/eLife.01958.005Figure 2.*MUL1* regulates mitochondrial morphology.(**A**) A schematic depicting the Drosophila *MUL1* genomic region (cytological location 64A4). *MUL1* coding and untranslated regions (dark and open rectangles, respectively) are depicted. The P element, *MUL1*^*EY*^, inserted in the 5′ UTR, is shown as an inverted triangle. The deleted region in the *MUL1*^*A6*^ allele is indicated by parentheses. (**B**) RT PCR shows that flies carrying the *MUL1*^*EY*^ allele have detectable but reduced levels of *MUL1* transcripts. However, no *MUL1* transcript is detected in flies homozygous for the *MUL1* deletion, *MUL1*^*A6*^. (**C**) qPCR shows that *MUL1*^*EY*^ allele has approximately a 60% reduction of *MUL1* transcript compared to the wild-type (WT). No *MUL1* transcript is detected in flies homozygous for *MUL1*^*A6*^. (**D**) *MUL1* RNAi line reverses the suppression of *PINK1* mutant mitochondrial phenotypes due to *MUL1* overexpression. (**E**) Muscle fibers stained with mitoGFP in green and actin in red. Compared with the WT, flies homozygous for the *MUL1* deletion or expressing *MUL1* RNAi show slightly elongated mitochondria. In contrast, when *MUL1* is overexpressed using the Mef2-Gal4 driver, mitochondria are significantly smaller. (**F**) Salivary glands, with cell boundaries labeled with rhodamine phalloidin in red, and mitoGFP in green. In WT, mitochondria are tubular and evenly distributed. In contrast, in cells expressing *MUL1* RNAi (driven by OK6-Gal4) mitochondria are fewer in number and found in clumps. In contrast, *MUL1* overexpression (also driven by OK6-Gal4) results in fragmented mitochondria and irregular cell boundaries. (**G**) Quantification of mitochondrial number and size in salivary glands (mean ± SEM, n \> 6 larvae for each genotype). \* Significantly different from wild-type, p\<0.05 (One-way ANOVA with Tukey\'s multiple comparisons test).**DOI:** [http://dx.doi.org/10.7554/eLife.01958.005](10.7554/eLife.01958.005)

We examined phenotypes due to loss-of-function and overexpression of *MUL1* in the IFM, which is a cellular syncytium, and in salivary glands, in which a number of individual cells contain an extensive tubular mitochondrial reticulum. Cells from *MUL1* null mutant flies, or flies in which *MUL1* RNAi is expressed, have mildly elongated mitochondria, while those from flies overexpressing *MUL1* have small and fragmented mitochondria ([Figure 2E--G](#fig2){ref-type="fig"}). Thus, *Drosophila MUL1* has a mild pro-fission function, as with mammalian *MUL1* ([@bib5]).

MUL1 binds to Mfn and negatively regulates its levels through ubiquitination {#s2-3}
----------------------------------------------------------------------------

Next, we asked whether Drp1, Mfn or both serve as MUL1 targets. Previous work suggested that MUL1 positively regulates Drp1\'s pro-fission activity through sumoylation-dependent protein stabilization ([@bib28]; [@bib5]). Surprisingly, overexpression of *MUL1* did not change Drp1 levels ([Figure 3A](#fig3){ref-type="fig"}). In contrast, overexpression of *MUL1* led to a reduction in Mfn levels ([Figure 3B](#fig3){ref-type="fig"}). Analysis of larval lysates from mutants showed that loss of *MUL1* results in an increase in Mfn levels, as does loss of *PINK1* or *parkin*, which serve as positive controls ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Knockdown of *MUL1* in *Drosophila* S2 cells also resulted in an increase in Mfn levels ([Figure 3C](#fig3){ref-type="fig"}).10.7554/eLife.01958.006Figure 3.MUL1 physically binds to Mfn, and promotes ubiquitination-mediated Mfn degradation.(**A** and **B**) Western blots and quantifications of Drp1 and Mfn levels in vivo. Analysis of lysates from thoraces show that *MUL1* overexpression reduces Mfn levels (**B**) but not Drp1 levels (**A**). The data are shown as the mean ± SEM from three experiments (each experiment was done with lysate from 8 thoraces for each genotype). The statistical analysis was done using One-way ANOVA with Tukey\'s multiple comparisons test. ns: not statistically significant. \*\* Significantly different, p\<0.01. (**C**) Western blots of Mfn levels in S2 cells either not treated or treated with control*, PINK1, parkin* or *MUL1* RNAi. Quantification of relative Mfn levels shows that there is an increase in Mfn levels in cells treated with RNAi to *PINK1, parkin,* or *MUL1* (mean ± SEM, \*\* Significantly different from cells not treated with RNAi, p\<0.01, One-way ANOVA with Tukey\'s multiple comparisons test). (**D**) Co-immunoprecipitation using lysates from S2 cells transfected with the indicated constructs. The INPUT represents 2% of total lysate to monitor protein expression (top panel). MUL1-GFP is co-immunoprecipitated with Mfn-myc using both anti-GFP and anti-Myc antibodies. Mfn-myc also co-immunoprecipitates with HA-Parkin, which serves as a positive control. The interaction between Mfn-Myc and MUL1-GFP was specific, as confirmed by separate immunoprecipitation control experiments ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). (**E**) Mfn ubiquitination levels in S2 cells. S2 cells are treated with dsRNA designed to silence various genes and transfected with Mfn-Flag. Immunoprecipitation was performed with anti-Flag antibody, and Western blots were probed with anti-Ubiquitin antibody and an anti-Flag antibody. Relative ubiquitination levels compared to control are shown below (mean ± SEM). \*\* Significantly different from control, p\<0.01 (One-way ANOVA with Tukey\'s multiple comparisons test). In S2 cells, Mfn is highly ubiquitinated. RNAi of *MUL1* or *parkin* results in reduced levels of ubiquitnated Mfn. Two independent *MUL1* RNAs are utilized to knockdown *MUL1*, which yield the same results. (**F**) In *PINK1* mutant thoraces, where Mfn levels are increased, *MUL1* overexpression (driven by Mef2-Gal4) reduces the increased Mfn levels. Relative Mfn levels compared to control are shown below (mean ± SEM). \*\* Significantly different, p\<0.01 (One-way ANOVA with Tukey\'s multiple comparisons test).**DOI:** [http://dx.doi.org/10.7554/eLife.01958.006](10.7554/eLife.01958.006)10.7554/eLife.01958.007Figure 3---figure supplement 1.MUL1 co-immunoprecipitates with Mfn in S2 cells.(**A**) Western blot analysis of co-immunoprecipitation. S2 cells were transfected with empty vector, Mfn-myc, GFP, or MUL1-GFP as indicated. Cells were harvested and lysed, and 2% of lysates were subjected to Western blot to monitor protein expression, shown as INPUT. For the rest of lysates, immunoprecipitations were performed with antibodies to Myc or GFP, and Western blots were probed with antibodies to GFP or Myc. In lysates from S2 cells transfected with both MUL1-GFP and Mfn-myc, MUL1-GFP is co-immunoprecipitated with Mfn-myc using both anti-GFP and anti-Myc antibodies. However, GFP is not co-immunoprecipitated with Mfn-myc.**DOI:** [http://dx.doi.org/10.7554/eLife.01958.007](10.7554/eLife.01958.007)

Next, we determined if MUL1 and Mfn interact physically, and if MUL1 regulates Mfn levels through ubiquitination. Overexpressed MUL1 co-immunoprecipitated with overexpressed Mfn from *Drosophila* S2 cell lysates. Parkin was used as a positive control and co-immunoprecipitated with Mfn as previously reported ([@bib54]; [@bib70]). These physical interactions are specific to MUL1 and Mfn rather than the tags utilized ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). To assay ubiquitination, Flag-tagged Mfn was expressed in S2 cells exposed to dsRNA targeting *MUL1* or *parkin* in the presence of the proteasome inhibitor MG132 ([Figure 3E](#fig3){ref-type="fig"}). In control cells, highly ubiquitinated Mfn was observed. When cells were treated with two different dsRNAs against *MUL1*, ubiquitinated Mfn levels were dramatically reduced, similar to those observed in *parkin* RNAi-treated cells, which serve as a positive control. Finally, we observed that the increased Mfn levels seen in the *PINK1* mutant flies were reduced when *MUL1* was overexpressed ([Figure 3F](#fig3){ref-type="fig"}), strengthening our argument that MUL1 suppresses *PINK1* mutant phenotypes through reduction of Mfn levels. Together, these results suggest that MUL1 suppresses *PINK1/parkin* phenotypes by reducing Mfn levels through its ubiquitination-dependent degradation.

*mfn* overexpression, but not loss of *drp1*, results in phenotypes similar to those of *PINK1* or *parkin* mutants; and these phenotypes are suppressed by *MUL1* overexpression {#s2-4}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Previous studies showed that downregulation of *mfn* or overexpression of *drp1* could suppress *PINK1* and *parkin* mutant phenotypes in *Drosophila* ([@bib15]; [@bib53]; [@bib65]). Parkin has also been shown to bind and ubiquitinate Mfn, promoting Mfn degradation ([@bib22]; [@bib54]; [@bib59]; [@bib70]; [@bib8]; [@bib25]). While increased Mfn levels are observed in *PINK1* or *parkin* mutants ([@bib54]; [@bib70]), it is unclear if these increased *mfn* levels are sufficient to cause the phenotypes observed in *PINK1* or *parkin* mutants. It is also unclear if a decrease in the levels of *drp1*, which can result in increased mitochondrial size through loss of fission, results in a phenotypically equivalent effect.

To address these questions, we generated transgenic flies carrying UAS-*mfn* (also called *Marf*, CG3869) and obtained two *drp1* null alleles, *drp1*^*1*^ and *drp1*^*2*^ ([@bib61]). Overexpression of *mfn* under the control of the muscle-specific (*mef2*) GAL4 driver resulted in organismal lethality. To circumvent this lethality, we also generated a new Gal4 driver, IFM-GAL4, in which GAL4 expression is driven specifically in the IFM ([Figure 4F--J](#fig4){ref-type="fig"} for IFM-GAL1, vs [Figure 4A--E](#fig4){ref-type="fig"} for mef2-GAL4), using regulatory sequences from the *flightin* gene. Since the IFMs are not required for viability, knockdown of essential genes using IFM-GAL4 does not cause lethality in flies (data not shown).10.7554/eLife.01958.008Figure 4.Generation and expression of the IFM-GAL driver; *mfn* overexpression, but not loss of *drp1*, induces *PINK1/parkin*-mutant like pathology.(**A**--**J**) Different developmental stages of flies expressing GFP under Mef2-Gal4 (**A**--**E**) or IFM-Gal4 (**F**--**J**). (**A**) Third instar larvae show GFP expression in whole body muscles. (**B**) At the early pupal stage, GFP is expressed in a similar pattern as in larvae. However, the GFP expression pattern become more specific at the late pupal stage (**C**), in which the strongest GFP signal is seen in the thorax, and a weaker signal is observed in the head and abdomen (arrows). (**D**) In an adult fly, dorsal view shows GFP signal in the thorax, upper abdomen and legs. (**E**) GFP is also expressed in adult head and legs, marked with arrows. (**F**) Flies expressing GFP under IFM-Gal4 show no GFP expression in third instar larvae, or in early pupae (**G**). (**H**) GFP is strongly expressed only in the thorax at the late pupal stage, but not in other areas (arrows). (**I**) In the adult fly, GFP signal is highly concentrated in the thorax. No GFP expression in abdomen and legs is observed, arrows. (**J**) In contrast to GFP expression under Mef2-Gal4, IFM-Gal4 does not express in adult head or legs, as indicated with arrows. (**K**--**P**, **T**--**Y**) Confocal images of muscle double labeled with mitoGFP (green) and phalloidine (red) (**K**--**M**, **T**--**V**), or those labeled with mitoGFP and TUNEL (red) at lower magnification (**N**--**P**, **W**--**Y**), respectively. (**Qa**--**Sb**) EM images of mitochondria in muscle. Single mitochondrion from the black-boxed area in **Qa**, **Ra**, **Sa** is shown in Qb, Rb, Sb. Scale bars: 1 µm (**Qa**, **Ra**, **Sa**) and 0.5 µm (**Qb**, **Rb**, **Sb**). Compared with wild-type (**K** and **N**), *parkin* null mutant (**L** and **O**) shows overall reduced levels of mitoGFP signal, large mitochondrial clumps, and muscle cell death. Similar phenotypes are observed with *mfn* overexpression (**M** and **P**), and these phenotypes are suppressed by *MUL1* overexpression (**T** and **W**). As a control, *parkin* overexpression also suppresses phenotypes due to *mfn* overexpression (**U** and **X**). Importantly, *drp1* null (*drp1*^*1*^*/drp1*^*2*^) mutant muscle does not have any mitochondrial clumping or TUNEL-positivity seen in loss of *parkin* function or *mfn* overexpression (**V** and **Y**). *mfn* overexpression is driven by IFM-Gal4. Scale bars: 5 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.01958.008](10.7554/eLife.01958.008)

Interestingly, overexpression of *mfn* in the IFM results in phenotypes ([Figure 4M,P,Sa,Sb](#fig4){ref-type="fig"}) similar to those of *PINK1* or *parkin* mutants; mitoGFP clumps, TUNEL-positive muscle cell death, and broken mitochondrial cristae when examined at the EM level ([Figure 1D′,E′,G′a,G′b](#fig1){ref-type="fig"}). In contrast, while loss of *drp1* results in an increase in mitochondrial size, no muscle cell death or degeneration is observed ([Figure 4V,Y](#fig4){ref-type="fig"}). Importantly, *MUL1* overexpression ([Figure 4T,W](#fig4){ref-type="fig"}), as with *parkin* overexpression ([Figure 4U,X](#fig4){ref-type="fig"}), suppressed the phenotypes associated with *mfn* overexpression. Together, these results show that overexpression of *mfn*, but not loss of *drp1*, leads to phenotypes similar to those due to lack of *PINK1* or *parkin*, suggesting a direct link between increased Mfn levels and pathology.

*MUL1* acts in parallel to the *PINK1/Parkin* pathway {#s2-5}
-----------------------------------------------------

Our observations that *MUL1* overexpression suppresses *PINK1* or *parkin* mutant phenotypes, and that both Parkin and MUL1 promote Mfn degradation, suggest two possible scenarios of how *MUL1* and *PINK1/parkin* interact. *MUL1* may be a downstream target of the *PINK1/parkin* pathway and upstream of *mfn*. Alternatively, *MUL1* could function in a parallel pathway to *PINK1/Parkin*, but with action on a common target such as Mfn. Characterization of double null mutants provides an effective way of distinguishing these possibilities. If *MUL1* functions in the same pathway as *PINK1*, double null mutants of *PINK1* and *MUL1* would be expected to show the same phenotype as the single mutant alone, as is observed in the case of *PINK1 parkin* double mutants ([@bib12]; [@bib49]). Conversely, if *MUL1* and *PINK1/parkin* act in parallel pathways, the phenotypes of double null mutants may be stronger than those of single mutants.

We generated *PINK1 MUL1* and *parkin MUL1* double mutants*.* Several lines of evidence show that double mutants have significantly enhanced phenotypes as compared to those of single mutants alone. First, *PINK1 MUL1* and *parkin MUL1* double null mutants show a high frequency of pupal lethality as compared with single mutants (data not shown), while double null mutants of *PINK1 parkin* have the same level of viability as single mutants ([@bib12]; [@bib49]). Second, a thoracic indentation observed in *PINK1* or *parkin* null mutants is much more severe in *PINK1 MUL1* and *parkin MUL1* double null mutants. In contrast, *PINK1 parkin* double null mutants show the same degree of thoracic indentation as *PINK1* or *parkin* single mutants alone ([Figure 5A--G](#fig5){ref-type="fig"}). Third, at the cellular level, *PINK1 MUL1* and *parkin MUL1* double null mutants have highly elongated and interconnected mitochondria, as determined using anti-mitochondrial ATPase antibodies. These mitochondrial phenotypes are very different from those of *PINK1*, *parkin*, or *MUL1* mutants ([Figure 5I--O](#fig5){ref-type="fig"}). *PINK1 parkin* double null mutants show similar mitochondrial morphology phenotypes as *PINK1* or *parkin* single mutants alone ([Figure 5O](#fig5){ref-type="fig"} vs [Figure 5J,M](#fig5){ref-type="fig"}). Fourth, ATP levels in *parkin MUL1* double null mutants were further reduced compared to those of *parkin* or *MUL1* single null mutants ([Figure 5Q](#fig5){ref-type="fig"}). Fifth, the ability of *parkin* overexpression to rescue *PINK1* mutants is not dependent on *MUL1*, and *MUL1* overexpression can still suppress *PINK1* mutants in the absence of *parkin* ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Sixth, knockdown of both *MUL1* and *parkin* in S2 cells further reduces Mfn ubiquitination below levels seen with knockdown of *MUL1* or *parkin* alone ([Figure 5R](#fig5){ref-type="fig"}). Seventh, *PINK1 MUL1* and *parkin MUL1* double null mutants have higher Mfn levels as compared to single null mutants of *MUL1*, *PINK1*, or *parkin* ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Finally, knockdown of *mfn* in the background of *parkin MUL1* double mutants almost completely rescues the thoracic indentation and mitochondrial phenotypes of *parkin MUL1* double mutants ([Figure 5H,P](#fig5){ref-type="fig"}). These genetic observations, in combination with biochemical findings that MUL1 physically interacts with Mfn, and that loss of *MUL1* results in decreased ubiquitination of endogenous Mfn and increased Mfn levels, indicate that *MUL1* acts in parallel to the *PINK1/parkin* pathway to regulate a common target Mfn.10.7554/eLife.01958.009Figure 5.*MUL1* acts in parallel to the PINK1/parkin pathway.(**A**--**H**) Images of thoraces of various mutants. Arrows point to thoracic indentations due to muscle degeneration. *PINK1 MUL1* and *parkin MUL1* double mutants have more severe thoracic indentation compared to either mutant alone. Remarkably, the severe thoracic indentation phenotype in *parkin MUL1* double mutants is almost completely suppressed when *mfn* is also knocked down. (**I**--**P**) Mitochondria are labeled using an anti-ATP synthase antibody in the IFM. While *PINK1*, *parkin*, and *MUL1* mutant show slightly elongated mitochondrial morphology, *PINK1 MUL1* and *parkin MUL1* double mutants exhibit highly elongated and interconnected mitochondria. These phenotypes can be suppressed by *mfn* knockdown. Instead of using mitoGFP, we utilized anti-ATPase antibodies that allow better visualization of the enhancement phenotypes seen with double mutants. (**Q**) Relative ATP levels in whole flies of various mutants (mean ±SEM from three experiments, five 5-day-old flies for each genotype). \*\* and \*\*\* significantly different from wild-type, p\<0.01 and p\<0.001, respectably (One-way ANOVA with Tukey\'s multiple comparisons test). \# Significantly different from *parkin* mutant and *MUL1* mutant, both p\<0.01 (Two-way ANOVA with Tukey\'s multiple comparisons test). (**R**) In vivo ubiquitination assay of Mfn. S2 cells were treated with the indicated RNAi, transfected with Flag-Mfn, and treated with proteasome inhibitor MG132. Immunoprecipitations were performed using anti-Flag antibody, and western blots were probed with antibodies against anti-Ubiquitin antibody (P4D1) or anti-Flag antibody. Relative ubiquitination levels compared to control are shown in the lower panel (mean ± SEM). \*\* and \*\*\* Significantly different from control, p\<0.01 and p\<0.001, respectably (One-way ANOVA with Tukey\'s multiple comparisons test). \# Significantly different from *MUL1* RNAi \#1 and *parkin* RNAi, both p\<0.01. & Significantly different from *MUL1* RNAi \#2 and *parkin* RNAi, p\<0.001 and p\<0.01, respectably (Two-way ANOVA with Tukey\'s multiple comparisons test). (**S**) Western blot analysis of Mfn levels in vivo and quantification (mean ± SEM from three experiments, eight third instar larvae for each genotype). \* and \*\* significantly different from wild-type, p\<0.05 and p\<0.01, respectably (One-way ANOVA with Tukey\'s multiple comparisons test). \# Significantly different from *parkin* mutant and *MUL1* mutant, both p\<0.01. & Significantly different from *PINK1* mutant and *MUL1* mutant, both p\<0.01 (Two-way ANOVA with Tukey\'s multiple comparisons test).**DOI:** [http://dx.doi.org/10.7554/eLife.01958.009](10.7554/eLife.01958.009)10.7554/eLife.01958.010Figure 5---figure supplement 1.*MUL1* acts in a parallel pathway to the *PINK1/parkin* pathway.(**A**--**H**) Confocal images of muscle fibers labeled with mitoGFP (green) and rhodamine phalloidin (red). Compared with wild-type (**A**), *PINK1* null mutant (**B**) or *parkin* RNAi (**C**) flies show large mitoGFP clumps. The abnormal mitochondrial phenotype in *parkin* RNAi flies is suppressed by *MUL1* overexpression (**D**). In *PINK1* null mutant muscles, overexpression of *MUL1* suppresses mitochondrial phenotypes (**E**), and *parkin* knockdown does not affect the suppression of *PINK1* mutant mitochondrial phenotype by *MUL1* overexpression (**F**). Similarly, *parkin* overexpression in *PINK1* mutant muscles suppresses mitochondrial phenotypes (**G**), and *MUL1* knockdown fails to reverse the suppression of *PINK1* mutant phenotype by *parkin* overexpression (**H**).**DOI:** [http://dx.doi.org/10.7554/eLife.01958.010](10.7554/eLife.01958.010)

The roles of *MUL1* in regulating mitochondrial morphology and mfn levels are conserved in human cells {#s2-6}
------------------------------------------------------------------------------------------------------

Next, we asked if MUL1-mediated mitochondrial morphology and Mfn regulation is conserved in human cells. We expressed human *MUL1* and *MUL1 LD* in HeLa cells ([Figure 6F](#fig6){ref-type="fig"}). Cells expressing MUL1 or MUL1 LD are GFP-positive and marked with asterisks ([Figure 6A--D″](#fig6){ref-type="fig"}). Cells expressing GFP-MUL1 showed peri-nuclear mitochondrial clustering ([Figure 6A--B](#fig6){ref-type="fig"}, asterisks), and mitochondria appeared small and globular in shape as compared to those in untransfected, GFP-negative cells ([Figure 6B--B″](#fig6){ref-type="fig"}). MUL1 LD neither causes mitochondrial clustering nor alters mitochondrial morphology ([Figure 6C--D″](#fig6){ref-type="fig"}, asterisks).10.7554/eLife.01958.011Figure 6.*MUL1*'s function in mitochondrial morphology and Mfn levels is conserved in human cells.(**A**--**D‴**) HeLa cells transfected with GFP-MUL1 (**A**--**B″**) or GFP-MUL1 LD (**C**--**D″**) are marked with asterisks, while cells not transfected serve as internal controls. Mitochondria are labeled with mitotracker in red (**B** and **D**). (**B′** and **B″**, **D′** and **D″**) Higher magnification images of mitochondria within white boxes in **B** and **D**. Cells expressing GFP-MUL1 have clustered mitochondria in the perinuclear region (**B**). Mitochondria are also small and fragmented (**B″**), as compared to cells not expressing GFP-MUL1 (**B′**). Importantly, GFP-MUL1 LD does not result in localization of mitochondria to the perinuclear region (**D**) or in mitochondrial fragmentation (**D′**). (**E**) Western blot analysis of Mfn1 and Mfn2 levels after CHX treatment. HeLa cells expressing scrambled shRNA or *MUL1* sh*MUL1* are treated with CHX. Mfn1 and 2 levels at each time point are normalized with Actin. The relative portion of remaining Mfn1 and 2 as compared to time point 0 was calculated and plotted (**E**). In cells expressing *MUL1* shRNA, Mfn1 and 2 levels after CHX treatment are more stable than those in cells expressing scrambled shRNA. (**F**) Expression of transfected GFP-MUL1 and GFP-MUL1 LD in HeLa cells, as detected using anti-GFP antibody. (**G**) Western blot analysis of endogenous MUL1 levels in HeLa cells stably expressing scrambled shRNA and *MUL1* shRNA. *MUL1* shRNA expressing cells have reduced levels of endogenous MUL1. (**H**) Human *MUL1* sequence and deletion in *MUL1* knockout (*MUL1*−/−) HeLa cells, generated using the CRISPR/Cas 9 system. Sequences targeting *MUL1* are highlighted in blue. Red letters indicate start codon. Red dashes represent deleted bases. Deleted eight base pairs include the start codon of MUL1. (**I)** Western blot analysis of Mfn1 and Mfn2 levels in wild-type and *MUL1*−/− HeLa cells treated with CHX for the indicated time. Remaining Mfn1 and Mfn2 levels at each time point were plotted below. (**J**) Western blot showing no MUL1 expression in *MUL1*−/− HeLa. Arrowhead points to MUL1 protein. Asterisk indicates a non-specific band.**DOI:** [http://dx.doi.org/10.7554/eLife.01958.011](10.7554/eLife.01958.011)

Mammals have two Mfn proteins, Mfn1 and Mfn2, both able to promote mitochondrial fusion ([@bib10]; [@bib17]). We monitored the fate of Mfn1 and Mfn2 in control HeLa cells and HeLa cells stably expressing small hairpin RNA against *MUL1* (*MUL1* shRNA) ([Figure 6E,G](#fig6){ref-type="fig"}). When cells were exposed to the protein synthesis inhibitor cycloheximide (CHX), Mfn1 and Mfn2 levels gradually decreased in control cells, but were dramatically stabilized in cells with decreased levels of *MUL1* ([Figure 6E](#fig6){ref-type="fig"}). To confirm the above result, we generated *MUL1* knockout HeLa cells ([Figure 6H](#fig6){ref-type="fig"}), which contain a deletion including the start codon in the *MUL1* genomic region, using the CRISPR/Cas 9 system ([@bib13]; [@bib30]; [@bib40]). Two independent anti-MUL1 antibodies confirmed no MUL1 expression in *MUL1* knockout cells ([Figure 6J](#fig6){ref-type="fig"} and data not shown). Similar to what was observed for the *MUL1* shRNA, Mfn1 and Mfn2 levels were also dramatically stabilized in *MUL1* knockout cells ([Figure 6I](#fig6){ref-type="fig"}). Together, these results suggest that the role of MUL1 in regulating Mfn stability and mitochondrial morphology is conserved in human cells.

*MUL1* does not affect Parkin-mediated mitophagy {#s2-7}
------------------------------------------------

The *PINK1/Parkin* pathway mediates mitophagy in HeLa cells ([@bib42], [@bib43]), mouse cortical neurons, and heart muscle ([@bib6]; [@bib11]). When cells are treated with a mitochondrial uncoupler, mitochondria lose their membrane potential. This leads to recruitment of Parkin to the depolarized mitochondria, ultimately resulting in autophagic degradation of these mitochondria. Because of the genetic interactions observed between *MUL1* and *PINK1*/*parkin* in *Drosophila*, we asked if *MUL1* was able to modulate Parkin-mediated mitophagy.

We induced mitophagy by exposing HeLa cells to antimycin A, which inhibits electron transport and depolarizes the mitochondrial membrane. Wild-type, *MUL1* knockout, and *PINK1* knockout (as a control) HeLa cells were transfected with YFP-Parkin and treated with DMSO or antimycin A for indicated time. In wild-type, without antimycin A treatment, Parkin mainly localizes in the cytosol ([Figure 7A](#fig7){ref-type="fig"}). However, following antimycin A treatment for 3 hrs, most Parkin was translocated to the mitochondria ([Figure 7B,D](#fig7){ref-type="fig"}). After 24 hrs of antimycin A treatment, Parkin was found dispersed in the cytosol and mitochondria were no longer observed, indicating that mitophagy had occurred ([Figure 7C,E](#fig7){ref-type="fig"}). To ensure there was no delay in mitophagy, we also assayed cells that were treated with antimycin A for 6, 12, 16 and 20 hrs ([Figure 7F](#fig7){ref-type="fig"}, data not shown). In all cells, mitophagy was observed at least 16 hrs after antimycin A treatment. No significant differences were observed in the fraction of Parkin recruited to mitochondria, or the fraction of mitochondria that underwent mitophagy, at any of these time points, for wild-type and *MUL1* knockout cells ([Figure 7B--F](#fig7){ref-type="fig"}). Knockdown of *MUL1* using shRNA also had no effect on Parkin translocation or mitophagy ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). As a control, *PINK1* knockout HeLa cells showed almost no Parkin localization to mitochondria and lack of mitophagy ([Figure 7B--F](#fig7){ref-type="fig"}). Similar results were obtained when cells were treated with carbonyl cyanide m-chlorophenylhydrazone (CCCP), which uncouples mitochondrial membrane potential (data not shown). Finally, *MUL1* overexpression also had no effect on Parkin translocation ([Figure 7G--H](#fig7){ref-type="fig"}) and did not block mitophagy (data not shown). Thus, neither loss of *MUL1* nor its overexpression altered Parkin translocation or mitophagy. These results are consistent with *MUL1* acting in parallel to *PINK1/parkin* in *Drosophila*, and suggest that *MUL1* regulates mitochondrial health through a distinct pathway.10.7554/eLife.01958.012Figure 7.Neither *MUL1* knockout nor overexpression affects Parkin-mediated mitophagy.(**A**--**C**) HeLa cells (control, *MUL1* knockout or *PINK1* knockout) were transfected with YFP-Parkin, treated with either DMSO or antimycin A, and immunostained with an anti-Tom20 antibody which labels mitochondria. (**A**) HeLa cells treated with DMSO as a control. (**B**) Following treatment with antimycin A for 3 hrs, Parkin is recruited to mitochondria, as shown by co-localization of Parkin and the mitochondrial marker. In *MUL1* null cells, Parkin recruitment to mitochondria is not affected, whereas in *PINK1* null cells (positive control), Parkin recruitment to mitochondria is abolished. (**C**) After 24 hrs of antimycin A treatment, Parkin returns to the cytosol and the mitochondrial signal disappears. In *MUL1* null cells, mitochondrial disappearance occurs similarly as with WT, whereas in *PINK1* null cells (positive control), mitochondria are not eliminated. (**D**--**E**) Quantification of cells with Parkin recruited to mitochondria after 3 hrs of antimycin A treatment (**D**) and with few or no mitochondria after 24 hr of antimycin A treatment (**E**) and after 16 and 20 hrs of antimycin A treatment (**F**). The data are shown as the mean ± SEM from three experiments (n ≥ 100 for each genotype). \*\*\* Significantly different from wild-type, p\<0.001. ns: not statistically significant (One-way ANOVA with Tukey\'s multiple comparisons test). While Parkin translocation and mitochondrial disappearance are significantly blocked in *PINK1* knockout cells, there is no significant difference between HeLa cells and *MUL1* knockout cells in these processes. (**G**) HeLa cells stably expressing YFP-Parkin and mito-RFP are transfected with Flag-MUL1, treated with DMSO or antimycin A, and immunostained with anti-Flag antibody. 3-hour antimycin A treatment causes Parkin localization to mitochondria in cells with or without *MUL1* expression. (**H**) Quantification of cells with Parkin recruited to mitochondria after 1.5 or 3 hrs Antimycin A treatment. Both 1.5 and 3 hrs of antimycin A treatments results in similar levels of Parkin recruitment to mitochondria. The data are shown as the mean ± SEM from three experiments (n ≥ 100 for each genotype). ns: not statistically significant (One-way ANOVA with Tukey\'s multiple comparisons test).**DOI:** [http://dx.doi.org/10.7554/eLife.01958.012](10.7554/eLife.01958.012)10.7554/eLife.01958.013Figure 7---figure supplement 1.*MUL1* knockdown does not affect Parkin-mediated mitophagy.(**A**) In contrast to what is observed with antimycin A, DMSO treatment does not result in a change in Parkin localization or mitochondrial morphology in HeLa cells expressing scrambled shRNA or *MUL1* shRNA. Parkin mainly localizes to the cytosol, shown in green, and does not co-localize with mitochondria, labeled in red. (**B**) HeLa cells that stably express scrambled shRNA or *MUL1* shRNA are transfected with YFP-Parkin, treated with antimycin A, and immunostained with anti-Tom20 antibodies, which label mitochondria. Following treatment with antimycin A for 3 hr, Parkin is recruited to mitochondria, as shown by co-localization of Parkin and the mitochondrial marker. After 24 hr of antimycin A treatment, Parkin returns to the cytosol and the mitochondrial signal disappears. (**C**) Quantification of cells with Parkin recruited to mitochondria after 1.5 or 3 hr of antimycin A treatment shows that there is no significant difference between HeLa cells that stably express scrambled shRNA and *MUL1* shRNA. (**D**) Quantification of the number of cells with few or no mitochondria after 24 or 48 hr of antimycin A treatment shows that there is no significant difference between the cell lines. The data are shown as the mean ± SEM from three experiments (n ≥ 100 for each genotype, One-way ANOVA with Tukey\'s multiple comparisons test).**DOI:** [http://dx.doi.org/10.7554/eLife.01958.013](10.7554/eLife.01958.013)

Loss of both *MUL1* and *parkin* aggravates mitochondrial damage and induces degeneration-like phenotypes in mouse cortical neurons {#s2-8}
-----------------------------------------------------------------------------------------------------------------------------------

To further test the hypothesis that *MUL1* functions in parallel to the *PINK1/parkin* pathway in mammalian cells, we investigated the effects of depleting both *MUL1* and *parkin*. As HeLa cells do not express Parkin, we turned to cultured mature cortical neurons. GFP-MUL1 localizes to the mitochondria in cell bodies and axons of the primary cortical neurons ([Figure 8A](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}).10.7554/eLife.01958.014Figure 8.Loss of both *MUL1* and *parkin* aggravates mitochondrial damage and induces degeneration-like phenotypes in mouse cortical neurons.(**A**) MUL1 targets mitochondria in the cell bodies and axons of mouse primary cortical neurons. Neuronal mitochondria were labeled by DsRed-Mito or stained with an antibody against mitochondrial marker, TOM20 or Cytochrome C ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). (**B**) Levels of endogenous MUL1 in neurons transfected with scrambled or *MUL1* shRNA. Note that partial suppression of endogenous MUL1 may reflect relative low transfection rate (20%) in the neuronal culture. (**C**--**F′**) Mitochondria in live cortical neurons were co-labeled by expressing CFP-mito, which targets all mitochondria, and by loading fluorescent dye TMRE, which stains healthy mitochondria dependent upon membrane potential (Δψ~m~). Loading TMRE also labels mitochondria in glia in the culture. The edges of neuron cell bodies are marked with white solid lines, and the nuclei are outlined with white dashed lines. In contrast to other neurons, *parkin* knockout neurons with *MUL1* knockdown show reduced TMRE intensity (**F** and **F′**), indicating decreased Δψ~m~. Scale bars: 10 µm. (**G**) Quantification of relative TMRE intensity. TMRE intensity measured from each group of neurons was normalized to WT neurons transfected with scrambled shRNA. The data are shown as the means ± SEM from three experiments. (n ≥ 12 for each group). \*\*\* Significantly different from wild-type neurons transfected with scrambled shRNA, p\<0.001. ns: not statistically significant (One-way ANOVA with Tukey\'s multiple comparisons test). \# Significantly different from wild-type neurons transfected with *MUL1* shRNA and *parkin* KO neurons transfected with scrambled shRNA, p\<0.001 and p\<0.01, respectively (Two-way ANOVA with Tukey\'s multiple comparisons test). (**H**--**M**) *MUL1* knockdown in *parkin* KO neurons results in enhanced fragmentation of neurites. Representative wild-type (**H** and **I**) and *parkin* KO (**J**--**K″**) cortical neurons transfected with scrambled or *MUL1* shRNA and labeled with GFP (confirming transfection of shRNA and labeling axons and dendrites). (**K′**--**K″**) Higher magnification of a white box in **K** showing the soma and proximal dendrites labeled with an anti-MAP2 antibody (red). Arrows point to the GFP- and MAP2-labeled dendrites, and arrowheads indicate GFP-labeled but MAP2-negative fragmented axons. Scale bars: 20 µm. (**L** and **M**) Quantitative analysis showing enhanced process fragmentation (**L**) and dendritic retraction (**M**). The data are shown as the means ± SEM from three experiments (process fragmentation phenotype: n ≥ 115 for each genotype, dendritic retraction: n ≥ 127 for each phenotype). \*, \*\*, and \*\*\* Significantly different from wild-type neurons transfected with scrambled shRNA, p\<0.05, p\<0.01, and p\<0.001, respectively. ns: not statistically significant (One-way ANOVA with Tukey\'s multiple comparisons test). \# Significantly different from wild-type neurons transfected with *MUL1* shRNA and *parkin* KO neurons transfected with scrambled shRNA, both p\<0.001. & Significantly different from wild-type neurons transfected with *MUL1* shRNA and *parkin* KO neurons transfected with scrambled shRNA, both p\<0.001 (Two-way ANOVA with Tukey\'s multiple comparisons test).**DOI:** [http://dx.doi.org/10.7554/eLife.01958.014](10.7554/eLife.01958.014)10.7554/eLife.01958.015Figure 8---figure supplement 1.MUL1 localizes to mitochondria in mouse cortical neurons.(**A**) Representative images showing co-localization of MUL1 with mitochondrial markers, TOM20 (upper panels) and Cytochrome C (lower panels), in the cell bodies and proximal dendrites of mouse cortical neurons.**DOI:** [http://dx.doi.org/10.7554/eLife.01958.015](10.7554/eLife.01958.015)10.7554/eLife.01958.016Figure 8---figure supplement 2.*MUL1* knockdown increases Mfn2 levels in mouse cortical neurons.(**A**--**D′**) Representative images of mouse cortical neurons (the cell bodies and proximal dendrites) labeled with anti-Cytochrome C (**A**--**D**) and Mfn2 (**A′**--**D′**) antibodies. (**E**) Quantitative analysis of relative Mfn2 levels normalized by Cytochrome C. The data are shown as the means ± SEM, n \> 20 for each genotype. \*, \*\*, and \*\*\* Significantly different from wild-type neurons transfected with scrambled shRNA, p\<0.05, p\<0.01, and p\<0.001, respectively (One-way ANOVA with Tukey\'s multiple comparisons test).**DOI:** [http://dx.doi.org/10.7554/eLife.01958.016](10.7554/eLife.01958.016)

The proper maintenance of the mitochondrial inner membrane potential (Δψ~m~) depends on the physiological function of the mitochondrial respiratory chain, and is crucial for generating ATP. Dissipation of the membrane potential is a strong indication of unhealthy mitochondria, which can lead to severe mitochondrial dysfunction and subsequent cell death. The Δψ~m~ can be measured using a fluorescent dye tetramethyl rhodamine ethyl ester (TMRE). We used two independent MUL1 shRNAs to suppress endogenous MUL1 expression in cortical neurons ([Figure 8B](#fig8){ref-type="fig"}). Cortical neurons expressing CFP-mito, from either wild-type mice co-expressing two independent MUL1 shRNA ([Figure 8D--D′](#fig8){ref-type="fig"}), or *parkin* gene KO mice co-expressing a scrambled shRNA ([Figure 8E--E′](#fig8){ref-type="fig"}), showed no significant decrease in the intensity of TMRE fluorescence ([Figure 8C,C′,G](#fig8){ref-type="fig"}). However, *parkin* KO neurons co-expressing *MUL1* shRNA showed a significant reduction of Δψ~m~ ([Figure 8F--F′,G](#fig8){ref-type="fig"}), suggesting that proper *MUL1* expression in primary cortical neurons is required to compensate for loss of *parkin* in maintaining mitochondrial integrity.

Next, we asked if *MUL1* knockdown alters Mfn2 levels in mouse cortical neurons. Neurons from wild-type or *parkin* KO mice were transfected with either scrambled shRNA or *MUL1* shRNA, followed by co-staining with anti-Cytochrome C and anti-Mfn2 antibodies. Relative Mfn2 intensity in individual neurons was analyzed by calculating the ratio of Mfn2 to Cytochrome C ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). Compared to wild-type neurons transfected with scrambled shRNA, wild-type neurons with *MUL1* shRNA, or *parkin* KO neurons with either scrambled shRNA or *MUL1* shRNA had an increased intensity ratio of Mfn2 to Cytochrome C. This suggests that MUL1\'s role in regulating Mfn2 levels is also conserved in neurons.

Finally, we investigated if loss of either *MUL1* or *parkin,* or loss of both, has any impact on cultured primary cortical neuron morphology. *MUL1* knockdown in cells from wild-type mice resulted in a minor increase in dendritic retraction but no significant process fragmentation as compared with wild-type cells ([Figure 8H,L,M](#fig8){ref-type="fig"}). Cortical neurons from *parkin* KO mice showed slightly increased process fragmentation but no dendritic retraction ([Figure 8J,L,M](#fig8){ref-type="fig"}), as compared with wild-type cells. In contrast, *MUL1* knockdown in *parkin* KO neurons resulted in a dramatic increase in the number of neurons with dendritic and axonal fragmentation and retraction ([Figure 8K--K″,L--M](#fig8){ref-type="fig"}; process fragmentation: total number of neurons examined: n \> 115 and n \> 127 each genotype for fragmentation and dendritic retraction analysis, respectively), indicative of early neurodegeneration. The observed phenotypes were confirmed using a second *MUL1* shRNA in *parkin* KO neurons (data not shown). These observations suggest that *MUL1* acts in parallel to the *PINK1/parkin* pathway to ensure mitochondrial integrity and function, thus maintaining neuronal health in primary cortical neurons.

Discussion {#s3}
==========

In summary, we identified *MUL1* as a robust suppressor of *PINK1/parkin* mutant phenotypes in *Drosophila*. *MUL1* overexpression, but not expression of a ligase-dead version, strongly suppresses *PINK1* and *parkin* mutant phenotypes. The mechanism of this suppression is unique in that *MUL1* does not act on *PINK1* or *parkin*, nor does it function as a downstream target. Rather, *MUL1* acts by suppressing *mfn* in parallel to the *PINK1/parkin* pathway ([Figure 9B](#fig9){ref-type="fig"}). *mfn* is crucial for actions downstream of *PINK1/parkin* to maintain mitochondrial function and tissue health ([Figure 9B](#fig9){ref-type="fig"}), as overexpression of *mfn* leads to pathology similar to lack of *PINK1/parkin* function. We hypothesize that the increase in the Mfn level needs to reach a threshold, such as that observed in the *PINK1/parkin* mutant backgrounds, but not in the *MUL1* null background, in order for overt muscle cell degeneration to occur ([Figure 9B](#fig9){ref-type="fig"}). Biochemically, MUL1 binds to Mfn, and loss of *MUL1* results in decreased ubiquitination of Mfn and increased Mfn levels. These observations suggest that MUL1 may directly ubiquitinate Mfn, leading to its degradation ([Figure 9A](#fig9){ref-type="fig"})*.* Alternatively, MUL1 may act via an intermediary that promotes Mfn ubiquitination and degradation. In *Drosophila*, overexpression of *MUL1* almost completely suppresses all aspects of the *PINK1/parkin* null phenotypes. Thus, treatments that manipulate *MUL1* expression or activity may have potential as therapeutics strategies.10.7554/eLife.01958.017Figure 9.Models for how *MUL1* interacts with *PINK1/parkin*.(**A**) Schematic depictions of how MUL1, PINK1, Parkin, and Mfn interact in the mitochondria. In mammalian cells, upon mitochondrial damage (CCCP or antimycin A treatment), PINK1 is stabilized onto the mitochondrial OM of damaged mitochondria, with its kinase domain facing the cytosol ([@bib68]). PINK1 recruits Parkin onto the OM, either through direct phosphorylation or indirect interaction with other proteins (not depicted here) ([@bib29]). Parkin then ubiquitinates multiple substrates on the OM, including Mfn. MUL1, a mitochondrial OM-anchored ligase with its RNF domain facing the cytosol, also mediates ubiquitination of Mitofusin. (**B**) The *PINK1/parkin* pathway and *MUL1* act in parallel to regulate *mfn*, and maintain mitochondrial function and tissue health. Reducing either *PINK1/parkin* or *MUL1* leads to increased levels of Mfn. Significant elevation of Mfn leads to mitochondrial dysfunction and tissue damage, similar to what is observed in *PINK1/parkin* mutants. Loss of both *PINK1/parkin* and *MUL1* leads to significantly higher Mfn levels, associated with severe mitochondrial dysfunction and tissue damage. OM: mitochondrial outer membrane; IM: mitochondrial inner membrane.**DOI:** [http://dx.doi.org/10.7554/eLife.01958.017](10.7554/eLife.01958.017)

In addition to showing that overexpression of *MUL1* compensates for lack of *PINK1/parkin* by downregulating Mfn levels, we have identified an evolutionarily conserved pathway and provide compelling evidence showing that endogenous levels of *MUL1* normally compensates for lack of *PINK1* or *parkin* in *Drosophila* and in mammals. Removal of *MUL1* in the *PINK1* or *parkin* null background significantly aggravates the phenotypes due to lack of *PINK1 or parkin* alone. Flies lacking *MUL1*, *PINK1* or *parkin* are viable, but *PINK1/MUL1* or *parkin/MUL1* double mutants manifest increased lethality with much more severe muscle degeneration, reduced ATP levels, defective mitochondrial morphology and increased Mfn levels. In addition, while *parkin* KO mature mouse cortical neurons or *MUL1* knockdown neurons show only mild neuronal phenotypes, neurons with *parkin* KO and *MUL1* KD show significantly diminished mitochondrial membrane potential, indicating mitochondrial dysfunction. They also show neurodegeneration-like phenotypes including axonal and dendritic fragmentation, and reduced mitochondrial distribution along processes. Finally, human HeLa cells, which have little or no endogenous Parkin, show a dramatic stabilization of Mfn when *MUL1* is eliminated.

Our findings may help to address an important puzzle in the field of PD research: why do *PINK1* or *parkin* knockout mice, or even *parkin/DJ-1/PINK1* triple knockout mice, bear only subtle phenotypes related to dopaminergic neuronal degeneration or mitochondrial morphology changes ([@bib48]; [@bib52]; [@bib51]; [@bib32]; [@bib18]; [@bib21]; [@bib24]; [@bib33]; [@bib1]). Our studies provide genetic and cellular clues that suggest compensation by *MUL1* may contribute to the subtle phenotypes in *PINK1* or *parkin* mutant mice. It will be interesting to determine whether *PINK1/MUL1* or *parkin/MUL1* double knockout mice show more severe PD-related pathology. Regarding PD therapies, optimizing the function of *MUL1* is likely to be beneficial for *PINK1/PARKIN* patients; upregulating *MUL1* may rescue the pathology due to lack of *PINK1* or *PARKIN*. In contrast, downregulating *MUL1* and/or mutations in *MUL1* may lead to disruption of this compensatory pathway in maintaining mitochondrial integrity and function, and result in accelerated disease progression.

Why do cells have multiple E3 ubiquitin ligases acting on a common target? Mfn is localized to the mitochondrial outer membrane (OM) ([Figure 9A](#fig9){ref-type="fig"}) and is a key molecule that regulates mitochondrial fusion in response to various cellular processes. Due to its importance, the level of Mfn is expected to be tightly regulated, and this may require several E3 ubiquitin ligases and deubiquitinases that respond to different stimuli ([@bib22]; [@bib50]; [@bib35]; [@bib39]; [@bib2]; [@bib19]). In the case of mitochondrial damage, Parkin translocates to depolarized mitochondria before it degrades Mfn ([Figure 9A](#fig9){ref-type="fig"}), thus preventing damaged mitochondria from fusing with healthy ones. As an E3 ligase anchored on the OM ([@bib38]; [Figure 9A](#fig9){ref-type="fig"}), MUL1 is constantly present in the vicinity of Mfn, thus mediating Mfn clearance either constitutively or in a regulated manner in response to different stress signals. It is also possible that multiple E3 ligases work in a concerted way to ensure constant Mfn levels. In our study, CHX treatment leads to the stabilization of Mfn levels in HeLa cells lack of *MUL1*. However, steady-state Mfn levels in these cells are not strongly affected. This may result from the existence of other pathways for Mfn regulation, such as direct transcriptional feedback regulation on Mfn expression, activities of deubquitinases, and additional E3 ligases. Similar considerations may explain the viability and apparently mild phenotypes of *MUL1* mutant flies. More severe phenotypes may be uncovered in flies lacking *MUL1* in response to specific stresses that cannot be buffered by other components.

A recent study reports that *MUL1* promotes mitophagy, when muscle wasting is stimulated in mice ([@bib39]). To monitor mitophagy, this study measured mitochondrial DNA content and emission of a mitochondrial fluorescent protein that changes color in an acidic environment such as the lysosome ([@bib39]). However, since these methods do not directly visualize mitochondrial fate, it is possible that the observations may reflect early signs of mitochondrial dysfunction or turnover of the indicator protein, rather than clearance of the mitochondria. Also, it is unknown whether *MUL1* interacts with the *PINK1/parkin* pathway to regulate the mitochondrial clearance. Our results show that overexpression or lack of *MUL1* does not affect Parkin-mediated mitophagy induced by mitochondrial damage in HeLa cells. This further strengthens our hypothesis that *MUL1* acts in *PINK1/parkin*-independent pathway for regulating mitochondrial quality control.

Given our observations, it will be interesting to ask if human mutations in *mfn1 or mfn2* that decrease their abilities to be targeted for ubiquitin-dependent degradation, or mutations in *MUL1*, result in susceptibility for PD. It will also be interesting to see if polymorphisms in *MUL1* that affect *MUL1* expression levels or activity occur in PD patients. In this regard, it is worth noting that MUL1 forms a complex with VPS35 and VPS26 ([@bib4]). Since mutations in *VPS35* have been identified in multiple PD families ([@bib62]; [@bib69]; [@bib34]; [@bib37]), it will be particularly interesting to determine if PD-associated mutations in *VPS35* have effects on *MUL1*-dependent degradation of Mfn. Finally, our observation that overexpression of *mfn* alone is sufficient to recapitulate key phenotypes associated with loss of *PINK1* or *parkin* suggests that inhibition of *mfn* may have important therapeutic potential for PD.

Materials and methods {#s4}
=====================

Molecular biology and constructs {#s4-1}
--------------------------------

To generate UAS-*MUL1*, an EST clone from the *Drosophila* Genome Research Center (DGRC), AT15655, was subcloned into the UASt vector using EcoR1 and Xho1. The *Drosophila* MUL1 ligase-dead mutant (MUL1 LD) was generated by mutating H307 to A via site-specific mutagenesis (Stratagene QuikChange II XL Kit; Stratagene, La Jolla, CA). To generate UAS-*mfn*, the EST clone from DGRC, RE04414, was subcloned into the UASt vector. For UAS-*MUL1*-GFP, UAS-*mfn*-myc, and UAS-HA-*parkin*, each gene\'s coding region was fused to a different tag using the gateway cloning system (Invitrogen, Carlsbad, CA). To silence *MUL1* and *drp1*, the coding regions of *MUL1* and *drp1* transcripts were targeted using a synthetic microRNA-based technology ([@bib9]; [@bib20]). PCR products of these miRNA precursors were cloned into pUASt. To generate IFM-GAL4, the regulatory region of the *flightin* gene was used. All constructs made were confirmed by DNA sequencing. To map *MUL1* imprecise excision lines, breakpoints were determined by genomic PCR followed by DNA sequencing. pAC-*mfn*-Flag was a gift from Dr Alexander J Whitworth ([@bib70]). Human MUL1 cDNA (BC010101) was purchased from ATCC and cloned into a pEGFP vector (Clontech, San Jose, CA) to generate GFP-*MUL1*. Flag-*MUL1* was generated by replacing the GFP tag with a Flag tag. Human MUL1 LD was generated by mutating H319 to A, which corresponds to *Drosophila* MUL1 H307A. Human *MUL1* shRNA constructs were purchased from OriGene. The *MUL1* shRNA sequences are 5′-CTTCAAGTCCTGCGTCTTTCTGGAGTGTG-3′ and 5′-GAAGGAGCTGTGCGGTCTGTTAAAG AAAC-3′.

*Drosophila* genetics and strains {#s4-2}
---------------------------------

CaSpeR-HA-*drp1* flies were a gift from Dr Hugo J Bellen ([@bib61]). *MUL1*^*EY12156*^, TRiP *parkin* RNAi, UAS-mitoGFP, Mef2-GAL4, OK6-GAL4 and TH-GAL4 flies were obtained from the Bloomington *Drosophila* Stock Center. *PINK1*^5^, *parkin*^25^, *dpk*^21^, UAS-*drp1* and UAS-*mfn* RNAi flies have been previously described ([@bib12]; [@bib15]). For experiments involving transgenic flies, constructs were injected into *w*^*1118*^ and multiple independent fly lines were generated and analyzed (Rainbow Transgenic Flies, Inc.). The deletion mutant *MUL1*^*A6*^ was generated by imprecise excision of *MUL1*^*EY12156*^ using previously described methods ([@bib26]). *Drosophila* strains were largely maintained in a 25°C humidified incubator.

RNA isolation, cDNA synthesis, and quantitative PCR (qPCR) {#s4-3}
----------------------------------------------------------

RNA was isolated from whole flies using the Macherry-Nagel Nucleospin RNA II kit. cDNA synthesis was performed using the Clontech RNA to cDNA EcoDry Premix Kit, using a combination of Oligo-dT and random hexamer priming. Quantitative PCR was performed using the BioRadiTaq Fast Sybr Green enzyme mix, 10 µl reactions in triplicate, on a Roche Light Cycler 480. Standard curves were generated for *MUL1* and two control genes, *rpl32* and *eIF1α*. [Table 1](#tbl1){ref-type="table"}.10.7554/eLife.01958.018Table 1.Primer sequences for qPCR**DOI:** [http://dx.doi.org/10.7554/eLife.01958.018](10.7554/eLife.01958.018)PrimersSequenceMUL1-FGCTATTGGTGAACTGGAGTTGGAMUL1-RAGCTTGAGTATCGTCGTTGTCTTrpl32-FTATGCTAAGCTGTCGCACAAATGrpl32-RGAACTTCTTGAATCCGGTGGGCeIF1α-FACTTCGCAAGAAGGTGTGGATTAeIF1α-RGTACGTCTTCAGGTTCCTGGC

Reverse transcription PCR (RT-PCR) {#s4-4}
----------------------------------

Total RNA was prepared as described above. RT-PCR was performed using Titanium One-Step RT-PCR Kit according to the manufacturer\'s instructions (Promega, Madison, WI). Primers used for RT-PCR are as follows in [Table 2](#tbl2){ref-type="table"}.10.7554/eLife.01958.019Table 2.Primer sequences for RT-PCR**DOI:** [http://dx.doi.org/10.7554/eLife.01958.019](10.7554/eLife.01958.019)PrimersSequenceMUL1 RT-FACACGAATCCGT TGCACTGMUL1 RT-RGCTCGTAGTTGTCGTAGACC

Immunofluorescence and confocal microscopy {#s4-5}
------------------------------------------

For analysis of muscle, thoraces of 1- to 2-day-old-adult flies were dissected and fixed in 4% paraformaldehyde in phosphate buffered saline (PBS). After thoraces were washed three times in PBS, muscle fibers were isolated and stained with rhodamine phalloidin (Invitrogen, 1:1000) in PBS+1% Triton X-100. For antibody staining, muscle fibers were permeabilized in PBS+0.1% Triton X-100, blocked in 5% normal goat serum in PBS, and incubated in primary and secondary antibodies diluted in 5% normal goat serum in PBS. For analysis of dopaminergic neurons, brains of 3-day-old male flies were dissected and fixed in 4% paraformaldehyde in PBS. Blocking, primary and secondary antibody staining were performed as described previously ([@bib66]). To analyze mitochondria in salivary glands, salivary glands of third instar larvae were dissected, fixed in 4% paraformaldehyde in PBS, and stained with rhodamine phalloidin. The following primary antibodies were used: mouse anti-ATP Synthase (Mitosciences, Eugene, OR), chicken anti-HA (Millipore, Billerica, CA), mouse anti-Tyrosine Hydroxylase (Immunostar Hudson, WI). All images were taken on a Zeiss LSM5 confocal microscope.

TUNEL assay {#s4-6}
-----------

Adult male flies were aged for 5 days at 25°C. Thoraces of the flies were dissected and fixed in 4% paraformaldehyde in PBS. Muscle fibers were dissected and subsequently permeabilized and blocked in T-TBS-3% BSA (T-TBS: 0.1% Triton X-100, 50 mM Tris-Cl \[pH 7.4\], 188 mM NaCl). After blocking, TUNEL staining was carried out using an In Situ Cell Death Detection Kit according to the manufacturer\'s instructions (Roche, Switzerland).

Embedding, sections, Toluidine blue staining, and transmission electron microscopy {#s4-7}
----------------------------------------------------------------------------------

Thoraces from 3-day-old male flies were dissected, fixed in paraformaldehyde/glutaraldehyde, postfixed in osmium tetraoxide, dehydrated in ethanol, and embedded in Epon. After polymerization of Epon, blocks were cut to generate 1.5-µmthick sections using a glass knife, or 80-nm thick sections using a diamond knife on a microtome (Leica, Germany). Toluidine blue was used to stain 1.5-µm -thick tissue sections. Thin sections (80-nm thick) were stained with uranyl acetate and lead citrate, and examined using a JEOL 100C transmission electron microscope (UCLA Brain Research Institute Electron Microscopy Facility). At least six thoraces were examined in each sample.

Quantification of mitochondrial number and size in salivary glands {#s4-8}
------------------------------------------------------------------

Images were taken on a Zeiss LSM5 confocal microscope. Each cell in the image was outlined, and the outlined area was analyzed for mitochondrial number, average size and total area using the Analyze Particles function in ImageJ software (NIH). N = 8

*Drosophila* lysate preparation and western blotting {#s4-9}
----------------------------------------------------

Thoraces from adult flies or whole animals were homogenized in RIPA buffer containing protease inhibitors (Roche). Total protein concentration was measured using a Bradford assay kit (Bio-Rad, Hercules, CA), and the same amount of protein was loaded onto SDS-polyacryamide gels. The following primary antibodies were used for Western blots: mouse anti-myc (Millipore), mouse anti-HA (Millipore), mouse anti-Tubulin (Sigma, St. Louis, MO), rabbit anti-Actin (Sigma), mouse anti-Porin (mitosciences), and rabbit anti-Mfn (a generous gift from Dr Alexander J Whitworth).

S2 cell culture, transfection, and RNAi treatment {#s4-10}
-------------------------------------------------

S2 cells were cultured in Schneider\'s *Drosophila* Medium (Gibco, Grand Island, NY) with 10% fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin (Invitrogen). Cells were seeded a day before transfection, and transfections were performed using the Effectene kit according to the manufacturer\'s recommendations (Qiagen, Valencia, CA). pAC-GAL4 was transfected along with UAS-Mfn-myc, UAS-HA-parkin, and UAS-MUL1-GFP for protein expression. UAS vector was used as empty vector. Cells were harvested 2 days after transfection. Double-stranded RNA (dsRNA) against coding regions of *GFP*, *PINK1*, *parkin*, *MUL1*, and *mfn* were generated using the T7 RiboMax express RNAi system (Promega). Primers that were used to generate dsRNAs are described below. S2 cells were seeded and treated with dsRNAs in serum-free medium for 40 min. After dsRNA treatment, complete medium was added to the culture, and the culture was incubated for 2--3 days. [Table 3](#tbl3){ref-type="table"}.10.7554/eLife.01958.020Table 3.Primer sequences for the generation of dsRNA templates**DOI:** [http://dx.doi.org/10.7554/eLife.01958.020](10.7554/eLife.01958.020)PrimerSequenceGFP-F (control)TAATACGACTCACTATAGGGTGAACCGCATCGAGCTGAAGFP-R (control)TAATACGACTCACTATAGGGACTTGTACAGCTCGTCCATGPINK1-FTAATACGACTCACTATAGGGAATGTGACTTCTCCAGCGAPINK1-RTAATACGACTCACTATAGGGTCGTAGCGTTTCATCAGCAGparkin-FTAATACGACTCACTATAGGGGTACGCAAAATGCTGGAGCTparkin-RTAATACGACTCACTATAGGGTAGAGGCTTGGAGGCTTCATMUL1 \#1-FTAATACGACTCACTATAGGGCCACCAAGTCCACGCTTATTMUL1 \#1-RTAATACGACTCACTATAGGGTGATCCTGGGACAGAGTGTGMUL1 \#2-FTAATACGACTCACTATAGGGGATTGTGAAGCTGCATGAGCMUL1 \#2-RTAATACGACTCACTATAGGGAACACATGGTCGAAGAGGGA

Co-immunoprecipitation {#s4-11}
----------------------

S2 cells were lysed in RIPA buffer containing protease inhibitors (Roche), and Western blots were performed with 2% of lysates to check protein expression. Immunoprecipitations were performed with the rest of lysate using Dynabeads (Invitrogen) according to the manufacturer\'s instructions. Proteins bound to beads were eluted in SDS sample buffer, and Western blots were performed. Primary antibodies used include mouse anti-Myc (Millipore), rabbit anti-GFP (Invitrogen), rabbit anti-HA (Sigma), and rabbit anti-Actin (Sigma).

In vivo ubiquitination assay in S2 cells {#s4-12}
----------------------------------------

After treatment with dsRNA for 2 days, S2 cells were transfected with Mfn-Flag and incubated for 24 hr. Before harvest, cells were treated with the proteasome inhibitor MG132 (Millipore) for 4 hr. Cells were lysed and boiled in SDS lysis buffer (1% SDS, 150 mM NaCl, 10 mM Tris--HCl, pH 8.0) with protease inhibitors (Roche) for 10 min. Dilution buffer (10 mM Tris--HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% Triton) was added, and immunoprecipitations were performed using mouse anti-Flag antibody (Sigma). After immunoprecipitations, Western blots were probed with mouse anti-ubiquitin (Covance). Mouse anti-FK1 (Enzo Life Sciences, Farmingdale, NY) and anti-FLAG (Sigma) antibodies were used.

Protein purification and in vitro ubiquitination assay {#s4-13}
------------------------------------------------------

For in vitro ubiquitination assay, the glutathione S-transferase (GST)-tagged expression vectors pGex-MUL1 and pGEX-MUL1 LD were generated. GST fusion proteins (GST-MUL1 and GST-MUL1 LD) were expressed in *E. coli* and purified from inclusion body. The in vitro ubiquitination assay was performed using the following buffer: 25 mM Tris (pH 7.5), 5 mM MgCl2, 100 mM NaCl, 1 mM DTT, 0.05 mM MG132, 2 mM ATP, and 0.125 µg/µl Ubiquitin, with E1 (Rabbit, 0.5 µg/ml), E2 (extract from *E. coli* expressing UbcH5C), and presence or absence of GST-MUL1, or GST-MUL1 LD (as indicated). Reaction mixtures were incubated at 30°C for 2 hr, and reactions were terminated by boiling in SDS loading buffer.

Mammalian cell culture, transfection, and western blotting {#s4-14}
----------------------------------------------------------

HeLa cells that did or did not overexpress *parkin* were generous gifts from Dr David C Chan ([@bib8]). Cells were cultured in Dulbeco\'s modified Eagle\'s medium (DMEM, Gibco) containing 10% fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin (Invitrogen). Cells were plated a day before transfections, and transfections were performed using the Effectene kit (Qiagen) or X-tremeGENE 9 DNA Transfection Reagent (Roche) according to the manufacturer\'s recommendations. After transfections, Z-VAD-FMK (Santa Cruz Biotechnology, Santa Cruz, CA) was added to cultures every 24 hr to inhibit apoptosis. Cells were harvested 48 hr later and lysed in RIPA buffer containing protease inhibitors (Roche). Western blots were performed with the following primary antibodies: rabbit anti-human MUL1 (Sigma), mouse anti-Mfn1 (Abcam), mouse anti-Mfn2 (Abcam), rabbit anti-Actin (Sigma), and mouse anti-Porin (Mitosciences).

Parkin-mediated mitophagy assays {#s4-15}
--------------------------------

HeLa cells that did or did not stably express *MUL1* shRNA were seeded in chamber slides, respectively, and transfected with YFP-Parkin one day later. 24 hrs after transfection, cells were treated with DMSO or 40 µg/ml Antimycin A (Sigma) for 1.5, 3, 24, or 48 hrs as indicated to dissipate mitochondrial membrane potential. For *MUL1* overexpression, HeLa cells stably expressing YFP-Parkin and mitoRFP (a kind gift from Dr. Mark R Cookson) were seeded and transfected with Myc-MUL1 1 day later. Cells were treated with DMSO or 80 µg/ml Antimycin A for 1.5 or 3 hrs. After treatment of Antimycin A, cells were fixed in 10% Formalin solution (Sigma), permeabilized with 0.1% Triton X-100 in PBS, and blocked in PBS containing 5% fetal bovine serum. Primary and secondary antibody staining were performed in 5% fetal bovine serum + PBS. The following primary antibodies were used: mouse anti-Tom20 (BD), mouse anti-Flag (Sigma), rabbit anti-GFP (Invitrogen), and rabbit anti-Parkin (Abcam, Cambridge, MA). More than 100 cells for each experiment were counted for quantification, and the experiments were repeated twice. PINK1 knockout cells were a generous gift from Dr. Richard Youle. Western blot analysis confirmed that there is no PINK1 expression in *PINK1* knockout cells ([@bib44]; personal communication).

Generation of *MUL1* knockout (*MUL1*−/−) HeLa cells using CRISPR/Cas 9 system {#s4-16}
------------------------------------------------------------------------------

*MUL1* knockout HeLa cells were generated using the CRISPR/Cas system as previously described ([@bib13]). Briefly, *MUL1* targetting sequence 5′-GCCGCCGTCA TGGAGAGCGG-3′ was inserted into pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene). HeLa cells were seeded a day before transfection. Cells were transfected with the construct using X-tremeGENE 9 DNA transfection reagent (Roche) following manufacturer\'s instructions. 2 days after the transfection, cells were diluted and split into 48 well plates. Each colony was screened for deletions in *MUL1* by PCR and sequencing using a set of primers 5′-CGCCTCGAACCTGACACATAATAGG-3′ and 5′-GTCTGTAAAGCAAGGAGTG GAGTGG-3′. Two *MUL1* knockout cells were isolated. Both *MUL1* knockout cells have deletions including the start codon of *MUL1*, one with 228 base pair deletion and another with 8 base pair deletion. Both deletions result in frame shift and early termination of protein translation. Further western blot analysis using two different anti-MUL1 antibodies (Sigma) confirmed that there is no MUL1 expression in *MUL1*−/− cells.

Protein turnover {#s4-17}
----------------

HeLa cells that express scrambled shRNA or *MUL1* shRNA were treated with cycloheximide (Sigma) for 0, 2, 4, 6 hrs. After cycloheximide treatment, cells were harvested and lysed. Protein concentration of each lysate was determined by Bradford assay (Bio-Rad), and an equal amount of total protein was subjected to Western blot. Blots were probed with anti-Mfn1 (Abcam), anti-Mfn2 (Abcam) and Actin (Sigma) antibodies. Levels of Mfn2 and Actin were quantified using ImageJ.

Mouse cortical neuronal culturing, transfection, and immunocytochemistry {#s4-18}
------------------------------------------------------------------------

Animal care and use were carried out in accordance with NIH guidelines, NIH Manual 3040-2, Guide for the Care and Use of Laboratory Animals (National Research Council), Institutional Animal Care and Use Committee Guidebook (ARENA and OLAW) and approved by the NIH, NINDS/NIDCD Animal Care and Use Committee on 3/5/2012 (ASP\# 1303-9).

The work and submission for publication was approved by the Intramural Program of NINDS, NIH. Dissection of embryonic mouse brains and isolation of cortical neurons and plating were designed to be very quick with minimal enzymatic, mechanical, chemical, and oxidative damage, as described by [@bib6]. Cortices were dissected from E18-19 mouse embryos. Cortical neurons were dissociated by papain (Worthington) and plated on glial beds at a density of 50,000 cells per cm^2^ on polyornithine (Sigma) and Matrigel (BD Biosciences)-coated coverslips. Neurons were grown overnight in plating medium (5% FBS, insulin, glutamate, G5, 1 x B27 and beta-mercaptoethanol) supplemented with 100 x L-glutamine in Neurobasal (Invitrogen). Starting at DIV2, cultures were maintained in conditioned medium with half-feed changes of neuronal feed (1 × B27, 100 × L-glutamine and beta-mercaptoethanol in Neurobasal) every 3 days. Neurons were transfected with various constructs at DIV7-8 using calcium phosphate and processed for immunocytochemistry 72 hr (DIV10-11) post transfection.

For immunostaining, cultured cells were fixed with 4% formaldehyde (Electron Microscopy Sciences) and 4% sucrose (Sigma) in 1X phosphate-buffered saline (PBS) at 4°C for 30 min, washed three times with PBS for 5 min each, and then incubated in 0.2% saponin, 5% normal goat serum (NGS), and 2% bovine serum albumin (BSA) in PBS for 1 hr. Fixed cultures were incubated with primary antibodies in PBS with 1% BSA and 0.05% saponin at 4°C overnight. Cells were washed four times with PBS at RT for 5 min each, incubated with secondary fluorescent antibodies at 1:400 dilution in PBS with 1% BSA and 0.05% saponin for 60 min, re-washed with PBS, and then mounted with Fluoro-Gel anti-fade mounting medium (EMS) for imaging. Sources of antibodies are as follow: polyclonal antibodies against TOM20 (Santa Cruz), MUL1 (Sigma), Mfn2 (Cell Signaling, Danvers, MA); monoclonal antibodies against MAP2 (Millipore), GAPDH (Research Diagnostic, Hackensack, NJ), CytC (BD Biosciences, San Jose, CA); Alexafluor 546 and 633-conjugated secondary antibodies (Invitrogen). Confocal images were obtained using an Olympus Fluoview FV1000 microscope, oil immersion 63X objective (NA-1.45) with sequential-acquisition settings. Images were acquired using the same settings below saturation at a resolution of 1024X1024 pixels (12 bit). Z stacks were acquired using a step size of 0.37 µm from top to bottom, and brightest point projections were made. For quantification, data were obtained from at least three independent experiments and the number of cells used for quantification is indicated in the figures. All statistical analyses were performed using One-way or Two-way ANOVA with Tukey\'s multiple comparison test and are presented as mean ± SEM.

TMRE (tetramethyl rhodamine ethyl ester) staining {#s4-19}
-------------------------------------------------

To access mitochondrial potential on a single cell basis, mature cortical neurons DIV (10--11), both from wild-type (WT) and *parkin* knockout (KO), were incubated with the cationic lipophilic compound TMRE (50 nM) for 20 min in a 37°C CO~2~ incubator. Post treatment, cells were washed three times with imaging media and mounted for imaging. Confocal images were obtained using an Olympus confocal oil immersion 63x objective with the sequential-acquisition setting. The images were acquired within 30 min. For fluorescent quantification, image acquisition settings were below saturation at a resolution of 1024 × 1024 pixels (12 bit). Five to six sections were taken from the top-to-bottom of the specimen and brightest point projections were made. Morphometric measurements were performed using NIH ImageJ. Measured data were imported into Excel software for analysis. The thresholds in all images were set to similar levels. Fluorescence intensity of TMRE was expressed in corrected total cell fluorescence (CTCF) values. The mean intensity of TMRE in the soma of each group was normalized as a percentile ratio relative to that in WT cells expressing scrambled shRNA. Data were obtained from at least three independent experiments and the number of cells used for quantification is indicated in the figures. All statistical analyses were performed using one-way or two-way ANOVA with Tukey\'s multiple comparisons test and are presented as mean ± SEM.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "*MUL1* compensates for loss of *PINK1/parkin* in maintaining mitochondrial integrity" for consideration at *eLife*. Your article has been favorably evaluated by a Senior editor and 3 reviewers, including member of our Board of Reviewing Editors Ray Deshaies and reviewer Hugo Bellen, who agreed to reveal their identities.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

The manuscript from the Guo lab provides evidence that in *Drosophila*, the ubiquitin ligase *MUL1* acts in a pathway parallel to *PINK* and *parkin* to maintain low levels of mitofusin protein. These findings are of considerable interest to the biological function of parkin and the consequences of its mutation in neurodegenerative disease, and are likely to be of interest to a general audience. In evaluating the claims made by the authors, the reviewers were of the consensus opinion that several modifications to the experimental data are needed to bring the claims in-line with the evidence provided to support them, as noted below:

1\) [Figure 3E](#fig3){ref-type="fig"} appears to be the exact same blot as the first four lanes of Figure 5R. This is not acceptable. Since there is a quantification of the gel in [Figure 3E](#fig3){ref-type="fig"} beneath the gel with error bars, it should be possible to change the western blot in [Figure 3E](#fig3){ref-type="fig"} to one of the three repeat gels so it is not exactly the same gel shown as Figure 5R. Alternatively, the full figure could be shown in [Figure 3E](#fig3){ref-type="fig"} and the authors can refer back to the last 2 lanes when describing this result in the context of the rest of [Figure 5](#fig5){ref-type="fig"}.

2\) Test whether endogenous Mfn co-IPs with endogenous *MUL1*. This would strengthen the fairly weak conclusion of a "direct" activity of *MUL1* on Mfn.

3\) The lack of mitochondrial fusion in their drp1 RNAi in Figure 4P needs to be omitted or addressed in much more detail. If the authors with to sustain their claims regarding Drp1, they need to provide biochemical data to document that Drp1 is strongly silenced, and if it is not they would need to use a strong mutant or more potent RNAi to achieve a compelling loss-of-function.

4\) It is surprising that both *Parkin/Pink* and *Mul1* pathways ubiquitinate mitofusin but Mul1 is not required for mitophagy in their model. They should test mitophagy at intermediate points before all the mitochondria disappear (e.g., 6,12, and 18 hr). The present data do not exclude the possibility that mitophagy is delayed in *MUL1* mutant cells. The authors should also test whether antimycin A can trigger mitophagy in cells that overexpress *MUL1*, in the presence and absence of *Parkin* or *PINK*. For both of the experiments described above, it would be desirable to have a more quantitative read-out, such as immunoblots of mitochondrial matrix proteins.

5\) No data are presented to confirm that SUMO RNAi was effective in *PINK1* mutants suppressed by *MUL1* OE. Moreover, the data presented for wild type flies treated with SUMO RNAi is not quantitative. Given that this observation brings into question a published finding from the McBride lab, either the evidence for SUMO loss-of-function should be strengthened (e.g., by including blotting data) or the data should be removed.

In addition to these modifications to the data, there are a number of issues noted below that need to be addressed, but this can be done adequately by modifications to the text.

6\) There is some concern among the reviewers concerning how the findings are presented. For example, the authors say that *MUL1* compensates for loss of *Parkin* and that *MUL1* ensures mitochondrial integrity and function. This seems to be an excessively \'parkin-ocentric\' viewpoint, since it seems unlikely that MUL1 exists solely to compensate for the potential loss of *PINK* or *parkin*. The title and abstract should be modified to emphasize the parallel nature of the *PINK/parkin* and *MUL1* pathways.

7\) In the Results section the authors refer to a "ligase-dead" version of MUL1, but there is no citation or data to establish why this mutant should be ligase-dead, or that it is in fact ligase-dead.

8\) Provide more support for the claim in the Results section that visualization of mitochondrial ATPase is independent of mitochondrial import? Does assembly of ATPase holoenzyme rely on functional import pathway?

9\) Report the Y-axis on the graph in [Figure 5S](#fig5){ref-type="fig"} as Mfn:actin ratio. Essentially all of the "increase" in relative Mfn in the double mutant is not due to an increase in Mfn at all, but rather a decrease in actin. Is it possible to normalize the samples in some other way (total protein or some other housekeeping protein besides actin)?

10\) There was some divergence of opinion among the reviewers regarding the lack of a clear phenotype for mutant flies lacking *MUL1* (see comment \#1 of reviewer 3). The authors should at least comment on whether knockdown/knockout of MUL1 has any noticeable effect on mitochondrial morphology. The authors should also discuss possible physiological roles of *MUL1* that could be further tested. Related to this, the authors should expand on their model in the discussion to explain that Mitofusin degradation presumably needs to reach a threshold to observe a phenotype like that seen for *Pink1/Parkin* mutants.

11\) [Figure 6E, I](#fig6){ref-type="fig"}: despite the fact that both Mfn1 and Mfn2 are stabilized upon depletion or deletion of MUL1, the steady-state levels of these proteins are either not affected or barely affected. The authors should comment on this.

In addition to these points, each reviewer raised additional points for which a consensus opinion did not emerge regarding how they should be dealt with. In these cases it is left to the discretion of the authors as to how to respond. These are listed below:

*Reviewer 1*:

1\) The authors state, "\...supporting the idea that *MUL1* suppresses *PINK1* mutant phenotypes through reduction of Mfn levels". Although this is shown in wild type animals ([Figure 3B](#fig3){ref-type="fig"}), it was not shown in *PINK1* mutant. While this may seem like a detail one could argue it is a relatively important omission since it is at the core of their interpretation of how *MUL1* OE is exerting its effect.

2\) Figure 4M, O, S, U: does overexpression of parkin or MUL1 proteins reduce the level of overexpression of mitofusin protein?

3\) [Figure 5J, K](#fig5){ref-type="fig"}: why don\'t the *PINK1* and *parkin* mutants shown here look much better (i.e., much less defective) than those shown in multiple panels of [Figures 1, 2, and 4](#fig1 fig2 fig4){ref-type="fig"}?

4\) [Figure 8](#fig8){ref-type="fig"}: what effect do these various manipulations have on mitofusin levels in cortical neurons?

*Reviewer 2*:

This manuscript concludes that Mul1, a mitochondrial E3 ligase, ubiquitinates and causes proteosomal degradation of mitofusin in Drosophila and mammalian cells. Furthermore, *Mul1* loss exacerbates the phenotype of Parkin loss. The loss of *Mul1* is clearly shown in [Figure 5](#fig5){ref-type="fig"} to make the loss of *Parkin/Pink1* mutant flies worse, which indicates they work by different mechanisms. However, this is not surprising -- many mutations in flies will cause stress by different paths and exacerbate one another\'s phenotype. Therefore, the key issue is whether or not both *Mul1* and *Parkin* function by inducing the ubiquitination and elimination of mitofusin. *Mul1* decreases the expression level of Mfn1 but this may be indirect and cell free experiments could conclusively show *Mul1* ubiquitinates Mfn. However, cell free experiments seems to be beyond the scope of this manuscript. Why would increased Mfn level lead to the mitochondrial and cellular defects? Is this through decreased mitophagy? If not mitophagy what? MUL1 is not likely expressed simply to statically reduce the steady state level of Mfn. How MUL1 is regulated and why and when it ubiquitinates MFn (if it is direct) remains unexplored. Although there are clearly mysteries here, this is a very thorough genetic study with intriguing conclusions in need of only minor corrections.

*Reviewer 3*:

MUL1 compensates for loss of *PINK1/parkin* in maintaining mitochondrial integrity. In the present manuscript, Yun et al. uncover a parallel pathway to PINK1/parkin acting through MUL1. Both pathways converge on a shared target mitofusin to maintain mitochondrial integrity in both *Drosophila* and mammals. Recently, MUL1 was identified as a novel regulator of mitochondrial fission by activation of Drp1 through sumolyation and degradation of MFN1 and MFN2 through ubiquitination. In this manuscript the authors provide genetic evidence that MUL1 is required for mitofusin turnover in *Drosophila* and human cell lines. Moreover, MUL1 overexpression can suppress phenotypes associated with pink and parkin mutants through mitofusin degradation, suggesting a compensatory role for MUL1. As *Pink1/Parkin* also ubiquitinate mitofusin, they decided to test if MUL1 and *Pink1/Parkin* act in the same pathway. Double mutant of MUL1 with either *PINK1* or *parkin* have a more severe phenotype than the single mutants, which suggests that MUL1 and *Pink1/Parkin* act in parallel pathways. I believe the manuscript suitable for *eLife* if the authors address these concerns:

1\) The subtle phenotypes associated with *MUL1* mutants suggest a compensatory role of this pathway. The authors should highlight the importance of *MUL1* in physiological conditions. Can the authors document, either by loss of one copy of *Pink1* or *Parkin* or by stressing mitochondria, a stronger phenotype in *MUL1* mutants. They should test life span or fertility in *MUL1* mutants under normal and stressed conditions to provide a comparison with *pink/parkin* mutant phenotypes.

\[Editors\' note: further clarifications were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled "*MUL1* acts in parallel to the *PINK1/parkin* pathway in regulating mitofusin and compensating for loss of *PINK1/parkin*" for further consideration at eLife. Your revised article has been favorably evaluated by a Senior editor, a member of the Board of Reviewing Editors, and the original reviewers. The manuscript has been improved but there are some remaining issues that need to be addressed. The authors have addressed most of the comments that were raised in the original review, with one notable exception. The authors have not shown that there is a direct physical interaction between the endogenous Mul1 and Mfn proteins. The authors state that this is not possible, because there is no antibody against *Drosophila* Mul1 and the antibody against mammalian Mul1 does not work for IP. However, there are antibodies available against mammalian Mfn that have been reported to work for immunoprecipitation. This experiment should be done, as originally requested, or the authors should present a strong argument for why it cannot be done.

10.7554/eLife.01958.022

Author response

*1)* [*Figure 3E*](#fig3){ref-type="fig"} *appears to be the exact same blot as the first four lanes of Figure 5R. This is not acceptable. Since there is a quantification of the gel in* [*Figure 3E*](#fig3){ref-type="fig"} *beneath the gel with error bars, it should be possible to change the western blot in* [*Figure 3E*](#fig3){ref-type="fig"} *to one of the three repeat gels so it is not exactly the same gel shown as Figure 5R. Alternatively, the full figure could be shown in* [*Figure 3E*](#fig3){ref-type="fig"} *and the authors can refer back to the last 2 lanes when describing this result in the context of the rest of* [*Figure 5*](#fig5){ref-type="fig"}.

We agree with this point and thank the reviewer for pointing this out. We now added [Figure 3E](#fig3){ref-type="fig"} with one of the repeat gels.

*2) Test whether endogenous Mfn co-IPs with endogenous* MUL1*. This would strengthen the fairly weak conclusion of a "direct" activity of* MUL1 *on Mfn*.

This is a very reasonable experiment and we would like to be able to do this as well. However, there is no anti-*Drosophila MUL1* antibody available, which prevents us from carrying out this experiment in flies. We also tried the experiments using mammalian anti-*MUL1* antibodies in mammalian cells, but found the antibody not suitable for immunoprecipitation of endogenous proteins.

It is important to note that we have not made any strong argument that the interaction of MUL1 and Mfn is "direct". In the Discussion, we state "These observations suggest that MUL1 may directly ubiquitinate Mfn, leading to its degradation. Alternatively, *MUL1* may act via an intermediary that promotes Mfn ubiquitination and degradation".*3) The lack of mitochondrial fusion in their drp1 RNAi in Figure 4P needs to be omitted or addressed in much more detail. If the authors with to sustain their claims regarding Drp1, they need to provide biochemical data to document that Drp1 is strongly silenced, and if it is not they would need to use a strong mutant or more potent RNAi to achieve a compelling loss-of-function.* This is a great point.

In this revision, we have used flies with two different *drp1* null alleles (*drp1*^*1*^and *drp1*^*2*^, as previously reported by Vestreken et al.) instead of flies with *drp1* RNAi. Consistent with the RNAi results, flies with a complete loss-of-function of *drp1* do not show any TUNEL-positive cell death, which is distinct from lack of *PINK1* or *parkin*, or *mfn* overexpression. These panels are included as Figure 4V and Y.

*4) It is surprising that both* Parkin/Pink *and Mul1 pathways ubiquitinate mitofusin but Mul1 is not required for mitophagy in their model. They should test mitophagy at intermediate points before all the mitochondria disappear (e.g., 6,12, and 18 hr). The present data do not exclude the possibility that mitophagy is delayed in* MUL1 *mutant cells. The authors should also test whether antimycin A can trigger mitophagy in cells that overexpress* MUL1*, in the presence and absence of Parkin or PINK. For both of the experiments described above, it would be desirable to have a more quantitative read-out, such as immunoblots of mitochondrial matrix proteins*.

Following the reviewers' suggestion, we have now tested 4 additional time points (6, 12, 16 and 20 hours) in addition to 24 hours for mitophagy. We were unable to see any differences between *MUL1* null cells and wildtype cells. We have modified the text accordingly.

Regarding testing whether antimycin A can trigger mitophagy in cells that overexpress *MUL1*, in the presence and absence of *Parkin or PINK1*, we think that it is an important question. However, we believe that it is beyond the scope of this work. The focus of the mammalian work in this manuscript is to address the requirement and physiological roles of MUL1 in mitophagy, when expressed at physiological levels. We will address whether MUL1 is sufficient to induce mitophagy in future work. However, if Reviewers feel strongly that these experiments are absolutely required for publication, we will of course carry out the experiments and report back to you.

*5) No data are presented to confirm that SUMO RNAi was effective in* PINK1 *mutants suppressed by* MUL1 *OE. Moreover, the data presented for wild type flies treated with SUMO RNAi is not quantitative. Given that this observation brings into question a published finding from the McBride lab, either the evidence for SUMO loss-of-function should be strengthened (e.g., by including blotting data) or the data should be removed*.

This is an excellent point. After consideration, we decided to remove this part.

*6) There is some concern among the reviewers concerning how the findings are presented. For example, the authors say that* MUL1 *compensates for loss of* Parkin *and that* MUL1 *ensures mitochondrial integrity and function. This seems to be an excessively \'parkin-ocentric\' viewpoint, since it seems unlikely that* MUL1 *exists solely to compensate for the potential loss of* PINK *or parkin. The title and abstract should be modified to emphasize the parallel nature of the* PINK/parkin *and* MUL1 *pathways*.

We see the reviewers' point and have modified the title and text. The revised title is "*MUL1* acts in parallel to the *PINK1/parkin* pathway in regulating *mitofusin* and compensating for loss of *PINK1/parkin*". The revised Discussion also contains new paragraphs that discuss the role of *MUL1* in the context of its phenotypes.

*7) In the Results section the authors refer to a "ligase-dead" version of* MUL1*, but there is no citation or data to establish why this mutant should be ligase-dead, or that it is in fact ligase-dead*.

We thank reviewers for pointing this out. We have added the citation accordingly. In addition, we have added data from in vitro ubiquitination assays suggesting that *MUL1*, but not ligase-dead version, can self-ubiquitinate as [Figure 1--figure supplement 1](#fig1s1){ref-type="fig"}.

*8) Provide more support for the claim in the Results section that visualization of mitochondrial ATPase is independent of mitochondrial import? Does assembly of ATPase holoenzyme rely on functional import pathway*?

We see reviewers' point and deleted the sentence in the text. We have clarified it by adding the following sentence to the figure legend: "Instead of using mitoGFP, we utilized anti-ATPase antibody, which allows better visualization of the enhancement phenotypes seen with double mutants."

*9) Report the Y-axis on the graph in* [*Figure 5S*](#fig5){ref-type="fig"} *as Mfn:actin ratio. Essentially all of the "increase" in relative Mfn in the double mutant is not due to an increase in Mfn at all, but rather a decrease in actin. Is it possible to normalize the samples in some other way (total protein or some other housekeeping protein besides actin)*?

This is a great point raised by reviewers. We repeated the experiment and measured protein concentration. We also used Tubulin in addition to Actin to normalize the samples. The updated figure is shown as [Figure 5S](#fig5){ref-type="fig"}.

*10) There was some divergence of opinion among the reviewers regarding the lack of a clear phenotype for mutant flies lacking* MUL1 *(see comment \#1 of reviewer 3). The authors should at least comment on whether knockdown/knockout of* MUL1 *has any noticeable effect on mitochondrial morphology. The authors should also discuss possible physiological roles of* MUL1 *that could be further tested. Related to this, the authors should expand on their model in the discussion to explain that Mitofusin degradation presumably needs to reach a threshold to observe a phenotype like that seen for* Pink1/Parkin *mutants*.

The effects of *MUL1*on mitochondrial morphology were in fact shown in [Figure 2](#fig2){ref-type="fig"}. MUL1 overexpression results in small and fragmented mitochondria. Loss of MUL1 is viable, albeit with mild mitochondrial elongation. It is possible that Mfn levels are kept constant by several different pathways including *MUL1* and the *PINK1/parkin* pathway. Due to the redundancy of regulation, loss of *MUL1* only causes mild phenotypes. It is also possible that certain stresses can lead to more severe phenotypes in *MUL1* null flies. We have included this part in our Discussion.

This may result from the existence of other pathways for Mfn regulation, such as direct transcriptional feedback regulation on Mfn expression, activities of deubquitinases, and additional E3 ligases). Similar considerations may explain the viability and apparent mild phenotypes of *MUL1* mutant flies. More severe phenotypes may be uncovered in flies lacking *MUL1* in response to specific stresses that cannot be buffered by other components.

It is an excellent idea to expand on our model to discuss the phenotypic threshold and mfn levels, and we appreciate the Reviewers for this suggestion. We have included the following sentences in our Discussion.

We hypothesize that the increase in the Mfn level needs to reach a threshold, such as that observed in the *PINK1/parkin* mutant backgrounds, but not in the *MUL1* null background, in order for overt muscle cell degeneration to occur ([Figure 9B](#fig9){ref-type="fig"}).

*11)* [*Figure 6E, I*](#fig6){ref-type="fig"}*: despite the fact that both Mfn1 and Mfn2 are stabilized upon depletion or deletion of* MUL1*, the steady-state levels of these proteins are either not affected or barely affected. The authors should comment on this*.

This is a great suggestion and we added a paragraph in Discussion to address this.

Why do cells have multiple E3 ubiquitin ligases acting on a common target? Mfn is localized to the mitochondrial outer membrane (OM) ([Figure 9A) and is](#fig9){ref-type="fig"} a key molecule that regulates mitochondrial fusion in response to various cellular processes. Due to its importance, the level of Mfn is expected to be tightly regulated, and this may require several E3 ubiquitin ligases and deubiquitinases which respond to different stimuli {[@bib50] \#5648;[@bib35] \#5649;[@bib19] \#5650;[@bib22] \#1310;[@bib39] \#1337;[@bib2] \#5651}. In the case of mitochondrial damage, *Parkin* translocates to depolarized mitochondria before it degrades Mfn ([Figure 9A](#fig9){ref-type="fig"}), thus preventing damaged mitochondria from fusing with healthy ones. As an E3 ligase anchored on the OM ([@bib38]) ([Figure 9A](#fig9){ref-type="fig"}), *MUL1* is constantly present in the vicinity of Mfn, thus mediating Mfn clearance either constitutively or in a regulated manner in response to different stress signals. It is also possible that multiple E3 ligases work in a concerted way to ensure constant Mfn levels.

In our study, CHX treatment leads to the stabilization of Mfn levels in HeLa cells lack of *MUL1*. However, steady-state Mfn levels in these cells are not strongly affected. This may result from the existence of other pathways for Mfn regulation, such as direct transcriptional feedback regulation on Mfn expression, activities of deubquitinases, and additional E3 ligases. Similar considerations may explain the viability and apparent mild phenotypes of *MUL1* mutant flies. More severe phenotypes may be uncovered in flies lacking *MUL1* in response to specific stresses that cannot be buffered by other components.

*In addition to these points, each reviewer raised additional points for which a consensus opinion did not emerge regarding how they should be dealt with. In these cases it is left to the discretion of the authors as to how to respond*.

Reviewer 1:

*1) The authors state, "\...supporting the idea that* MUL1 *suppresses* PINK1 *mutant phenotypes through reduction of Mfn levels". Although this is shown in wild type animals (*[*Figure 3B*](#fig3){ref-type="fig"}*), it was not shown in* PINK1 *mutant. While this may seem like a detail one could argue it is a relatively important omission since it is at the core of their interpretation of how* MUL1 *OE is exerting its effect*.

We fully agree with the point raised by Reviewer 1. In the revision, we added [Figure 3F](#fig3){ref-type="fig"} to show that the increased Mfn levels in PINK1 mutants are reduced when MUL1 is overexpressed. This further strengthens our argument that MUL1 suppresses PINK1 mutant phenotypes through reduction of Mfn levels.

*2) Figure 4M, O, S, U: does overexpression of parkin or MUL1 proteins reduce the level of overexpression of mitofusin protein*?

Yes. The data are shown in [Figure 3B](#fig3){ref-type="fig"}.

*3)* [*Figure 5J, K*](#fig5){ref-type="fig"}*: why don\'t the* PINK1 *and* parkin *mutants shown here look much better (i.e., much less defective) than those shown in multiple panels of* [*Figures 1, 2, and 4*](#fig1 fig2 fig4){ref-type="fig"}?

We used anti-ATPase antibody instead of mitoGFP to visualize mitochondrial morphology in [Figure 5J, K](#fig5){ref-type="fig"}., which allows better visualization of the enhancement phenotypes seen in double mutants. To clarify this point, we now added the following sentence in the figure legend: "Instead of using mitoGFP, we utilized anti-ATPase antibodies, which allows better visualization of the enhancement phenotypes seen with double mutants."

*4)* [*Figure 8*](#fig8){ref-type="fig"}*: what effect do these various manipulations have on mitofusin levels in cortical neurons*?

Knockdown of MUL1 results in an increase in Mfn levels in mouse cortical neurons. In the Revision, we added [Figure 8--figure supplement 2](#fig8s2){ref-type="fig"} to demonstrate this

Reviewer 2:

*This manuscript concludes that* Mul1*, a mitochondrial E3 ligase, ubiquitinates and causes proteosomal degradation of mitofusin in* Drosophil*a and mammalian cells. Furthermore,* Mul1 *loss exacerbates the phenotype of* Parkin *loss. The loss of* Mul1 *is clearly shown in* [*Figure 5*](#fig5){ref-type="fig"} *to make the loss of* Parkin/Pink1 *mutant flies worse, which indicates they work by different mechanisms. However, this is not surprising -- many mutations in flies will cause stress by different paths and exacerbate one another\'s phenotype. Therefore, the key issue is whether or not both* Mul1 *and Parkin function by inducing the ubiquitination and elimination of mitofusin.* Mul1 *decreases the expression level of Mfn1 but this may be indirect and cell free experiments could conclusively show* Mul1 *ubiquitinates Mfn. However, cell free experiments seems to be beyond the scope of this manuscript. Why would increased Mfn level lead to the mitochondrial and cellular defects? Is this through decreased mitophagy? If not mitophagy what? MUL1 is not likely expressed simply to statically reduce the steady state level of Mfn. How MUL1 is regulated and why and when it ubiquitinates MFn (if it is direct) remains unexplored. Although there are clearly mysteries here, this is a very thorough genetic study with intriguing conclusions in need of only minor corrections*.

These are excellent questions for future studies.

Reviewer 3:

*\[...\] The subtle phenotypes associated with* MUL1 *mutants suggest a compensatory role of this pathway. The authors should highlight the importance of* MUL1 *in physiological conditions. Can the authors document, either by loss of one copy of* Pink1 *or* Parkin *or by stressing mitochondria, a stronger phenotype in* MUL1 *mutants. They should test life span or fertility in* MUL1 *mutants under normal and stressed conditions to provide a comparison with* pink/parkin *mutant phenotypes*.

These are good experiments and we plan to carry out these studies in the near future.

\[Editors\' note: further clarifications were requested prior to acceptance, as described below.\]

*The authors have addressed most of the comments that were raised in the original review, with one notable exception. The authors have not shown that there is a direct physical interaction between the endogenous Mul1 and Mfn proteins. The authors state that this is not possible, because there is no antibody against* Drosophila *Mul1 and the antibody against mammalian Mul1 does not work for IP. However, there are antibodies available against mammalian Mfn that have been reported to work for immunoprecipitation. This experiment should be done, as originally requested, or the authors should present a strong argument for why it cannot be done*.

We agree with the editors that it is important to demonstrate a direct physical interaction between the endogenous MUL1 and Mfn. We have made repeated attempts to carry out this experiment in mammalian cells, using both anti-MUL1 and anti-Mitofusin antibodies. However, we have not been able to detect consistent binding between the endogenous proteins. It is possible that the interaction is too weak or transient, and that it therefore evades detection in our system, even though we can detect interactions between the two proteins when both are overexpressed.

It may be useful to provide a point of comparison with another well-established Mfn-binding protein, Parkin. None of the papers detailing interactions between Parkin and Mfn, and Parkin-dependent ubiquitination of Mfn, have shown these interactions using Co- IP between endogenous proteins ([@bib8]; [@bib22]; [@bib25]; [@bib54]; [@bib59]; [@bib70]). While this state of affairs is not ideal, and it is not our preferred form of rebuttal, it does highlight what may be a general difficulty in detecting interactions between endogenous Mfn and other proteins. This has not prevented people in the field, including us, from concluding that Parkin binds to Mfn.

Finally, we interpret our data cautiously in the Discussion: "These observations suggest that MUL1 may directly ubiquitinate Mfn, leading to its degradation. Alternatively, MUL1 may act via an intermediary that promotes Mfn ubiquitination and degradation".

[^1]: These authors contributed equally to this work.

[^2]: Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, United States.
